

Supporting Information

Novel Linker Variants of Antileishmanial / Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility

Andrew M. Thompson,^{*,†} Patrick D. O'Connor,^{†,^} Vanessa Yardley,[‡] Louis Maes,^{||} Delphine Launay,[#] Stephanie Braillard,[#] Eric Chatelain,[#] Baojie Wan,[§] Scott G. Franzblau,[§] Zhenkun Ma,^{‡,@} Christopher B. Cooper,[‡] and William A. Denny[†]

[†]*Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand*

[‡]*Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom*

^{||}*Laboratory for Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium*

[#]*Drugs for Neglected Diseases initiative, 15 Chemin Louis Dunant, 1202 Geneva, Switzerland*

[§]*Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States*

[‡]*Global Alliance for TB Drug Development, 40 Wall St, New York 10005, United States*

Current addresses

[^]*Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany*

[@]*TenNor Therapeutics Ltd, 218 Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China*

*Corresponding author

Email: am.thompson@auckland.ac.nz

Contents

Table S1. Complete (mean \pm standard deviation) *in vitro* antiparasitic and antitubercular data for the compounds of Table 1 (p S3)

Table S2. Complete (mean \pm standard deviation) comparative *in vitro* antiparasitic and antitubercular data for some recently reported analogues of **8** (p S4)

Additional SAR discussion (p S4)

Table S3. Complete (mean \pm standard deviation) *in vivo* efficacy data for selected analogues in the *L. don* mouse model (p S5)

Figure S1. Comparative *in vivo* efficacy of selected analogues against *L. don* in the VL mouse model at 50 mg/kg and 25 mg/kg (p S5)

Figure S2. Plasma concentration-time profiles for **65** and **66** in BALB/c mice, following intravenous dosing at 1 mg/kg or oral dosing at 25 mg/kg (p S6)

Figure S3. Plasma concentration-time profiles for **8** and **10** in Swiss Albino mice, following intravenous dosing at 1 mg/kg or oral dosing at 25 mg/kg (p S7)

Figure S4. Effect of lipophilicity on potency against *L. inf* or *Mycobacterium tuberculosis* (*M. tb*) for the compounds of Table 1 (p S8)

Schemes S1-S3. More detailed depictions of synthetic routes to the new linker analogues of Table 1 (pp S9-S11)

Experimental procedures and characterizations for the new compounds of Table 1, and assay protocols (pp S12-S27)

References for Supporting Information (pp S28-S29)

Table S4. Combustion analyses for the new compounds of Table 1 and intermediates (p S30)


Copies of ^1H and ^{13}C NMR spectra for representative examples, including key compounds (pp S31-S65)

Table S1. Complete *in vitro* antiparasitic and antitubercular data for the compounds of Table 1 (all data for **8**, **10**, **59** and **60** from ref S1; all data for **11** and **12** from ref S2).

Compd	IC ₅₀ (μM) ^{a,b}				Select. Index ^c	MIC ₉₀ (μM) ^{b,d}	
	<i>L. infantum</i>	<i>T. cruzi</i>	<i>T. brucei</i>	MRC-5		MABA	LORA
10	0.047 ± 0.021 ^e	0.061 ± 0.028 ^f	>64	>64	>1362	5.2 ± 2.6 ^g	4.7 ± 2.6 ^h
8	0.13 ± 0.05 ^e	0.14 ± 0	>64	>64	>492	0.94 ± 0.04	6.8 ± 3.1 ^f
11	0.13 ± 0.07 ^f	0.18 ± 0.05	>64	>64	>492	0.86 ± 0.10	7.0 ± 5.1
12	0.45 ± 0.05 ^f	0.45 ± 0.15	>64	>64	>142	1.3 ± 0.4	5.0 ± 3.2
15	0.15 ± 0.02 ^f	0.45 ± 0.03	>64	>64	>427	1.7 ± 0.3	10 ± 6
18	0.18 ± 0.07 ⁱ	0.50 ± 0.29	>64	>64	>356	0.17 ± 0.07	8.1 ± 5.0
20	0.29 ± 0.07 ^f	0.45 ± 0.24	>64	>64	>221	0.65 ± 0.21	10 ± 6
22	0.93 ± 0.54	1.2 ± 0.3	>64	>64	>69	7.2 ± 3.2	36 ± 5
24	0.22 ± 0.02 ^f	1.1 ± 0.5 ^f	>64	>64	>291	0.11 ± 0.01	6.5 ± 3.9 ^f
26	0.27 ± 0.02 ^f	0.65 ± 0.32 ^f	23 ± 0	52 ± 18 ^f	193	0.091 ± 0.034	6.9 ± 3.8
28	0.31 ± 0.02 ^f	0.51 ± 0.08	>64	>64	>206	0.23 ± 0.02	3.9 ± 2.6 ^f
30	0.48 ± 0.19	0.59 ± 0.34	>64	>64	>133	1.3 ± 0.4	8.2 ± 6.2
35	2.2 ± 0.5	4.2 ± 0.4	>64	>64	>29	12 ± 0	31 ± 10
40	0.13 ± 0	0.55 ± 0.02	>64	>64	>492	0.24 ± 0.01	7.1 ± 0.8
43	1.5 ± 0.8 ^f	3.8 ± 1.2	56 ± 5 ^f	>64	>43	(2.2)	(31)
44	1.4 ± 0.1	6.1 ± 0.6	59 ± 5	>64	>46	(2.5)	(32)
45	1.3 ± 0.2	4.4 ± 0.9	>64	>64	>49	0.82 ± 0.16	22 ± 9
46	9.9 ± 3.6	2.7 ± 0.8	>64	>64	>6.5	(31)	(54)
47	2.0 ± 0.1	6.5 ± 2.5	>64	>64	>32	1.8 ± 0.1	12 ± 1
48	1.7 ± 0.5	20 ± 11	>64	>64	>38	3.9 ± 0.3	14 ± 2
49	3.3 ± 1.2	3.6 ± 0.9	1.4 ± 0.7 ^f	>64	>19	0.61 ± 0.20 ^f	3.8 ± 0
51	1.4 ± 0	2.8 ± 0.1	9.2 ± 1.6	40 ± 12	29	0.82 ± 0.13	8.6 ± 1.9
53	1.8 ± 0.3	4.0 ± 0.3	36 ± 6	>64	>36	0.90 ± 0	19 ± 5
55	0.16 ± 0.02	1.8 ± 0.4	>64	>64	>400	0.90 ± 0.07	5.3 ± 0.1
57	2.2 ± 1.0	3.8 ± 1.4	>64	>64	>29	0.88 ± 0.06	14 ± 2
58	2.0 ± 0.1	2.0 ± 0.4	>64	>64	>32	5.5 ± 1.1	24 ± 2
59	0.12 ± 0.05 ^g	1.2 ± 0.7 ^f	>64	>64	>533	1.0 ± 0.5 ^f	7.5 ± 3.4 ^f
60	0.30 ± 0.07 ^f	0.75 ± 0.41 ^f	>64	>64	>213	0.55 ± 0.23 ^f	3.3 ± 1.7 ^f
64	0.49 ± 0.04	2.2 ± 0.5	46 ± 18	>64	>131	0.55 ± 0.30	3.7 ± 0.1
65	0.36 ± 0.22	0.88 ± 0.53	5.5 ± 1.6 ^f	>64	>178	0.58 ± 0.21	12 ± 3
66	0.36 ± 0.04	1.6 ± 0.3	33 ± 1 ^f	>64	>178	0.34 ± 0.02	7.3 ± 0.4
68	0.14 ± 0.01	2.3 ± 0.8	19 ± 11	>64	>457	0.085 ± 0.036	1.0 ± 0.1
69	0.20 ± 0	4.3 ± 2.1	48 ± 16	>64	>320	0.39 ± 0.21	2.9 ± 0.6
70	0.64 ± 0.10	1.7 ± 0.1	>64	>64	>100	(3.6)	(37)
71	0.18 ± 0.03	2.8 ± 0.3	32 ± 8	>64	>356	0.94 ± 0.01	7.3 ± 0.1
72	0.32 ± 0	1.7 ± 0.1	>64	44 ± 20	138	1.8 ± 0	6.3 ± 0.3
73	0.79 ± 0	1.6 ± 0.1	8.0 ± 0.3	43 ± 21	54	2.8 ± 0.8	3.4 ± 0.1
74	1.3 ± 0.8	2.1 ± 0.1	8.2 ± 0.1	>64	>49	1.7 ± 0.2	46 ± 18

^aIC₅₀ values for inhibiting the growth of *Leishmania infantum* (in mouse macrophages), *Trypanosoma cruzi* (on MRC-5 cells), and *Trypanosoma brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single test MIC data in parentheses) is the mean of N=2 measurements (± SD), unless noted. ^cSelectivity index: ratio of MRC-5 to *L. inf* IC₅₀ values. ^dMIC₉₀ against *M. tb* under aerobic (MABA) or hypoxic (LORA) conditions. ^eN=7. ^fN=3. ^gN=4. ^hN=5. ⁱN=6.

Table S2. Complete comparative *in vitro* antiparasitic and antitubercular data for some recently reported analogues of **8** (all data for **75** and **76** from ref S2).^{S2,S3}



Compd	Y	IC ₅₀ (μM) ^{a,b}				MIC ₉₀ (μM) ^{b,c}	
		<i>L. infantum</i>	<i>T. cruzi</i>	<i>T. brucei</i>	MRC-5	MABA	LORA
8	O	0.13 ± 0.05 ^d	0.14 ± 0	>64	>64	0.94 ± 0.04	6.8 ± 3.1 ^e
75	O ^f	0.098 ± 0.049 ^g	0.052 ± 0.001	>64	>64	0.59 ± 0.36	1.4 ± 0.2
76	O ^h	0.17 ± 0.09 ⁱ	0.34 ± 0.03	>64	>64	3.6 ± 0.8	18 ± 12
77	S	62 ± 3 ^j	0.46 ± 0.13 ^j	>64	>64	0.54 ± 0.35 ^e	4.3 ± 0.2
78	SO	41 ± 23 ^j	2.4 ± 1.0 ^j	18 ± 6	>64	(16)	(61)
79	SO ₂	>64	0.69 ± 0.01	>64	>64	(12)	>128
80	O	>64	0.54 ± 0	33 ± 1	>64	(29)	>128

^aIC₅₀ values for inhibiting the growth of *Leishmania infantum* (in mouse macrophages), *Trypanosoma cruzi* (on MRC-5 cells), and *Trypanosoma brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single test MIC data in parentheses) is the mean of N=2 measurements (± SD), unless otherwise noted. ^cMIC₉₀ against *M. tb* under aerobic (MABA) or hypoxic (LORA) conditions. ^dN=7. ^eN=3. ^f(7*R*)-Enantiomer. ^gN=8. ^h(7*S*)-Enantiomer. ⁱN=6. ^jN=4.

Additional discussion

Following on from our observation (in the manuscript) that “across all 7-Me linker derivatives, the association between VL potency and effectiveness against TB was only moderate”, we note that further SAR variances were encountered for a few heterocyclic analogues of **8** that we had recently studied^{S3} for Chagas disease (**77-80**; Table S2). In particular, replacement of the oxygen atom in the oxadiazole ring of **8** by sulfur (**77**) led to a 477-fold reduction in potency against *L. inf*, compared to a 1.6- to 1.7-fold *increased* effectiveness against *Mycobacterium tuberculosis* (*M. tb*), although this latter activity was greatly reduced (14- to >30-fold) upon S-oxidation (**78** and **79**). However, switching the nitroimidazole ring to a nitrotriazole ring (**80**) was poorly tolerated for both VL and TB, as noted previously for other structurally related scaffolds.^{S4,S5}

Table S3. Complete *in vivo* efficacy data for selected analogues in the *L. don* mouse model.

Compd	<i>In Vivo</i> Efficacy Against <i>L. don</i> (% Parasite Load Reduction at Dose in mg/kg) ^a					ED ₅₀ (95% C.I.) ^b
	50	25	12.5	6.25	3.13	
8		100 ± 0	100 ± 0	82.7 ± 8.0	25.1 ± 20.6	4.2 (3.7-4.6)
10		86.9 ± 5.9				
18	99.7 ± 0.2			29.5 ± 37.1		
26	58.3 ± 6.9					
44	70.6 ± 18.9					
51	36.0 ± 15.5					
66	99.95 ± 0.06	97.0 ± 3.4	7.1 ± 15.1			16.3 (14.5-18.4)
68		88.6 ± 7.5	40.4 ± 22.3			
69		51.0 ± 11.1	31.0 ± 8.4			

^aDosing was orally, once daily for 5 days consecutively; data are the mean percentage reduction of parasite burden in the liver (± standard deviation). ^bDose in mg/kg required to achieve a mean 50% reduction in parasite burden (with 95% confidence interval).

Figure S1. Comparative *in vivo* efficacy of selected analogues against *L. don* in the VL mouse model (liver burden only): (a) 50 mg/kg and (b) 25 mg/kg.




Figure S2. Plasma concentration-time profiles for **65** and **66** in BALB/c mice, following a single intravenous dose of 1 mg/kg or a single oral dose of 25 mg/kg in each case.





Figure S3. Plasma concentration-time profiles for **8** and **10** in Swiss Albino mice, following a single intravenous dose of 1 mg/kg or a single oral dose of 25 mg/kg in each case.







Figure S4. Effect of lipophilicity on potency against *L. inf* or *M. tb* for the compounds of Table 1.


a) CLogP vs potency against *L. inf* (complete dataset)



b) CLogP vs potency against *M. tb* (MABA assay; 7-Me subset only)




Scheme S1^a




^aReagents and conditions: (i) CoCl₂, CH₃CN, 65-75 °C, 1-3 d (17-97%); (ii) NaH, DMF, 0-20 °C, 2-4.3 h (or 50-70 °C, 2-3 h) (9-63%); (iii) HCOOH/Ac₂O, THF, 20 °C, 23 h (97%); (iv) Me₂S·BH₃, THF, 0-20 °C, 0.5 h, then 65 °C, 3.5 h (72%).

Scheme S2^a



^aReagents and conditions: (i) NaN₃, CTAB, MeOH, 20 °C, 45 min, then 40 °C, 17 h (73%); (ii) NaH, DMF, 0-20 °C, 2.5 h (70%); (iii) PPh₃, aq dioxane, 12-20 °C, 1 d (**38**: 48%, **39**: 32%); (iv) 4-OCF₃PhCHO, NaBH₃CN, AcOH, DMF, 0-20 °C, 21 h (50%); (v) PPh₃, DEAD, DPPA, DMF, 0-20 °C, 45 h (83%); (vi) PPh₃, ArCOCl (or 4-OCF₃PhOCH₂COCl), CH₂Cl₂, 20 °C, 1.5-2.2 h (51-84%); (vii) HS(CH₂)₃SH, Et₃N, MeOH, CH₂Cl₂, 15-20 °C, 12 h (83%); (viii) 3-OCF₃PhCOCl or RPhSO₂Cl, DIPEA, DMF, 0-20 °C, 3-19 h (46-81%); (ix) PPh₃, 4-OCF₃PhNH₂, 2 M TEAB, dioxane, 12-20 °C, 35 h (14-17%); (x) 4-OCF₃BnNCO, DIPEA, Bu₂Sn(OAc)₂, DMF, 20 °C, 16 h (93%); (xi) 4-NO₂PhOCOCl, pyridine, CH₂Cl₂, 0-20 °C, 20 h (98%); (xii) **38**, DMAP, DIPEA, DMF, 20 °C, 44 h (71%); (xiii) PPh₃, Boc-ON, CH₂Cl₂, 0-20 °C, 1 d (67%); (xiv) TFA, CH₂Cl₂, 20 °C, 7 h (100%).

Scheme S3^a



^aReagents and conditions: (i) NaI, acetone, 56 °C, 2 h, then 20 °C, 15 h (96%); (ii) **62**, NaH, DMF, 0-20 °C, 80 min (4%); (iii) ArNCO, CuCl, DMF, 20 °C, 32-52 h (44-98%).

Experimental Section

Combustion analyses were executed by the Campbell Microanalytical Laboratory, University of Otago, Dunedin, New Zealand. Melting points were measured using an Electrothermal IA9100 melting point apparatus and are as read. NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400 MHz for ^1H and 100 MHz for ^{13}C and were referenced to Me_4Si or solvent resonances. Chemical shifts and coupling constants were listed in units of ppm and hertz, respectively. High-resolution electrospray ionisation mass spectrometry (HRESIMS) was performed on a Bruker micrOTOF-Q II mass spectrometer or an Agilent 6530 Q-TOF mass spectrometer coupled to an Agilent 1200 series HPLC system. Low-resolution atmospheric pressure chemical ionisation (APCI) mass spectra were determined for organic solutions using either a ThermoFinnigan Surveyor MSQ mass spectrometer coupled to a Gilson autosampler or an Agilent 6120 Quadrupole LC/MS connected to an Agilent 1260 Infinity autosampler and quaternary pump. Optical rotations were measured on a Schmidt + Haensch Polartronic NH8 polarimeter. Column chromatography was carried out on silica gel (Merck 230-400 mesh) and thin-layer chromatography was completed on aluminum-backed silica gel plates (Merck 60 F₂₅₄), with visualization of components by UV light (254 nm), I_2 , or KMnO_4 staining. Tested compounds (including batches screened *in vivo*) were $\geq 95\%$ pure, as verified by combustion analysis and/or by HPLC performed on an Agilent 1100 system with diode array detection, using a 150 mm x 3.2 mm Altima 5 μm reversed phase C8 or C18 column. Combustion analyses indicated by the symbols of the elements were within $\pm 0.4\%$ of the theoretical values.

General Procedure A: Synthesis of arylamino alcohols from epoxides (intermediates 14, 17, 19, 21, 23, 25, 27, 29 and 34)

A mixture of the epoxide (**13** or **16**, 600 mg, 1.0 equiv), aryl amine (1.2-2.4 equiv) and anhydrous cobalt(II) chloride (0.2-0.9 equiv) in anhydrous acetonitrile (10 mL) was stirred at 70 °C for 48 h. The resulting cooled mixture was added to ice-water (100 mL) and extracted with CH_2Cl_2 (5 x 100 mL). The combined extracts were evaporated to dryness under reduced pressure and the residue was chromatographed on silica gel (0-2% $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to afford the required products.

General Procedure B: Ring closure of arylamino alcohols (target compounds 15, 18, 20, 22, 24, 26, 28, 30 and 35)

Sodium hydride (60% in mineral oil, 1.5 equiv) was added to a solution of the alcohol (**14**, **17**, **19**, **21**, **23**, **25**, **27**, **29**, or **34**, 1.0 equiv) in anhydrous DMF (1 mL/60 mg of alcohol) under N_2 at 0 °C. The mixture was quickly degassed and resealed under N_2 and then stirred at 20 °C for 4.3 h. The resulting mixture was rapidly cooled (CO_2 /acetone), quenched with ice/aqueous NaHCO_3 (10 mL), added to brine (100 mL), and extracted with CH_2Cl_2 (6 x 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was repeatedly chromatographed on silica gel (CH_2Cl_2 or 0-2% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ or 33-67% Et_2O /petroleum ether and Et_2O or 0-50% EtOAc /petroleum ether) as necessary to afford the required products.

General Procedure C: Direct synthesis of amides from azides (target compounds 43, 44, and 46-48)

A solution of triphenylphosphine (1.2 equiv) in anhydrous CH_2Cl_2 (2 x 0.5 mL) was added dropwise to a stirred mixture of the azide (**37** or **42**, 120 mg, 1.0 equiv) and the acid chloride (2.0 equiv) in anhydrous CH_2Cl_2 (3 mL) under N_2 . The mixture was stirred at 20 °C for 100

min, then added to ice/aq NaHCO₃ (50 mL), and extracted with CH₂Cl₂ (4 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel (0-75% EtOAc/petroleum ether and EtOAc) to afford the required products.

General Procedure D: Direct synthesis of ureas from azides (target compounds 49 and 51)

A fresh solution of triethylammonium bicarbonate (~2 M, 3.3 equiv) and triphenylphosphine (1.8 equiv) were successively added to a mixture of the azide (**37** or **42**, 1.0 equiv) and 4-(trifluoromethoxy)aniline (1.3-3.0 equiv) in dioxane (1 mL/14 mg of azide) at 12 °C. The mixture was stirred at 20 °C for 35 h in a sealed vial, then transferred to a flask (in MeOH/CH₂Cl₂) and evaporated to dryness under reduced pressure (at 30 °C). The residue was chromatographed on silica gel (0-10% MeOH/CH₂Cl₂) to afford the required products.

General Procedure E: Synthesis of sulfonamides from the Boc-protected amine (target compounds 57 and 58)

Trifluoroacetic acid (1.2 mL) was added to a stirred suspension of Boc derivative **56** (58 mg, 1.0 equiv) in anhydrous CH₂Cl₂ (1.2 mL). The resulting solution was stirred at 20 °C for 7 h in a sealed vial and then the solvents were removed under a stream of N₂ gas. The oily residue was treated with sodium carbonate (10 equiv) in MeOH (3 mL), stirring at 20 °C for 3 min, then transferred to a flask (in MeOH/CH₂Cl₂) and evaporated to dryness under reduced pressure (at 30 °C). The residue was chromatographed on silica gel (0-8% MeOH/CH₂Cl₂) to afford amine **38** as a hygroscopic yellow oil. This oil was evaporated twice from toluene, then dissolved in anhydrous DMF (2 mL), sealed under N₂, and cooled in ice. *N,N*-Diisopropylethylamine (5.3 equiv) and the required arylsulfonyl chloride (3.2 equiv) were successively added (dropwise with stirring), and the mixture was stirred at 20 °C for 3 h, then quenched with ice/aqueous NaHCO₃ (50 mL) and extracted with CH₂Cl₂ (5 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel (0-0.5% MeOH/CH₂Cl₂) to afford the required products.

General Procedure F: Synthesis of O-carbamates from alcohols (target compounds 65, 66 and 68-74)

The aryl isocyanate (1.6 equiv) was added to a solution of the alcohol (**41**, **63**, **67**, or *ent*-**67**, 1.0 equiv) in anhydrous DMF (1 mL/80 mg of alcohol) under N₂. Copper(I) chloride (0.1-0.2 equiv) was added and the mixture was quickly degassed and resealed under N₂ and then stirred at 20 °C for 33 h. The resulting mixture was diluted with ice-water (5 mL) and then added to brine (50 mL) and extracted with CH₂Cl₂ (6 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel (0-10% EtOAc/CH₂Cl₂) to afford the required products.

Syntheses of arylamino derivatives 15-35 (Scheme 1)

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-[[4-(trifluoromethoxy)phenyl]amino]butan-2-ol (14). Reaction of 2-chloro-4-nitro-1-[2-(oxiran-2-yl)ethyl]-1*H*-imidazole^{S1} (**13**) (216 mg, 0.992 mmol), 4-(trifluoromethoxy)aniline (316 mg, 1.78 mmol) and anhydrous cobalt(II) chloride (100 mg, 0.770 mmol), using General Procedure A, gave **14** (303 mg, 77%) as a yellow oil; ¹H NMR [(CD₃)₂SO] δ 8.55 (s, 1 H), 7.03 (br d, *J* = 8.5 Hz, 2 H), 6.61 (br d, *J* =

9.0 Hz, 2 H), 5.83 (br t, $J = 5.7$ Hz, 1 H), 5.04 (d, $J = 5.3$ Hz, 1 H), 4.25-4.10 (m, 2 H), 3.72-3.55 (m, 1 H), 3.04 (ddd, $J = 13.6, 6.3, 6.0$ Hz, 1 H), 2.99 (ddd, $J = 13.7, 6.5, 6.0$ Hz, 1 H), 2.09-1.97 (m, 1 H), 1.89-1.73 (m, 1 H); APCI MS calcd for $C_{14}H_{14}Cl_2F_3N_4O_4$ m/z $[M + Cl]^-$ 431, 429, found 431, 429.

***N*-[(2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-**

(trifluoromethoxy)aniline (15). Reaction of alcohol **14** (302 mg, 0.765 mmol) and NaH (48 mg, 1.20 mmol), using General Procedure B at 20 °C for 2 h, gave **15** (26 mg, 9%) as a pale yellow solid: mp 181-183 °C; 1H NMR $[(CD_3)_2SO]$ δ 8.06 (s, 1 H), 7.07 (br d, $J = 8.3$ Hz, 2 H), 6.71 (br d, $J = 9.0$ Hz, 2 H), 6.23 (br t, $J = 6.2$ Hz, 1 H), 4.69-4.60 (m, 1 H), 4.15 (ddd, $J = 12.6, 5.8, 2.6$ Hz, 1 H), 4.05 (ddd, $J = 12.5, 11.3, 5.0$ Hz, 1 H), 3.49-3.35 (m, 2 H), 2.33-2.23 (m, 1 H), 2.12-1.99 (m, 1 H). Anal. ($C_{14}H_{13}F_3N_4O_4$) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-2-methyl-1-[[4-(trifluoromethoxy)phenyl]-

amino]butan-2-ol (17). Reaction of 2-chloro-1-[2-(2-methyloxiran-2-yl)ethyl]-4-nitro-1*H*-imidazole^{S1} (**16**) (600 mg, 2.59 mmol), 4-(trifluoromethoxy)aniline (460 μ L, 3.43 mmol), and anhydrous cobalt(II) chloride (70.7 mg, 0.545 mmol), using General Procedure A at 68 °C, gave **17** (887 mg, 84%) as a yellow oil; 1H NMR ($CDCl_3$) δ 7.79 (s, 1 H), 7.06 (br d, $J = 8.9$ Hz, 2 H), 6.66 (br d, $J = 9.0$ Hz, 2 H), 4.32-4.16 (m, 2 H), 3.98 (br t, $J = 6.7$ Hz, 1 H), 3.19 (dd, $J = 13.2, 7.3$ Hz, 1 H), 3.13 (dd, $J = 13.1, 6.0$ Hz, 1 H), 2.13 (ddd, $J = 13.8, 9.7, 6.2$ Hz, 1 H), 1.98 (ddd, $J = 13.5, 10.0, 6.2$ Hz, 1 H), 1.88 (br s, 1 H), 1.37 (s, 3 H); HRESIMS calcd for $C_{15}H_{16}ClF_3N_4NaO_4$ m/z $[M + Na]^+$ 433.0680, 431.0704, found 433.0668, 431.0691.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-**

(trifluoromethoxy)aniline (18). Reaction of alcohol **17** (886 mg, 2.17 mmol) and NaH (131 mg, 3.28 mmol), using General Procedure B, gave **18** (143 mg, 18%) as a light yellow solid: mp (CH_2Cl_2 /pentane) 149-150 °C; 1H NMR $[(CD_3)_2SO]$ δ 8.06 (s, 1 H), 7.04 (br d, $J = 8.3$ Hz, 2 H), 6.75 (br d, $J = 9.1$ Hz, 2 H), 6.11 (br t, $J = 6.5$ Hz, 1 H), 4.16 (ddd, $J = 13.0, 5.9, 4.7$ Hz, 1 H), 4.08 (ddd, $J = 13.1, 9.7, 5.3$ Hz, 1 H), 3.38 (d, $J = 6.5$ Hz, 2 H), 2.26 (ddd, $J = 14.4, 9.7, 6.1$ Hz, 1 H), 2.08 (dt, $J = 14.2, 4.9$ Hz, 1 H), 1.40 (s, 3 H); ^{13}C NMR $[(CD_3)_2SO]$ δ 148.2, 147.4, 142.2, 138.4 (q, $J_{C-F} = 1.9$ Hz), 121.9 (2 C), 120.3 (q, $J_{C-F} = 254.0$ Hz), 117.7, 112.5 (2 C), 82.5, 50.6, 39.5, 27.2, 21.6. Anal. ($C_{15}H_{15}F_3N_4O_4$) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-[(4-chlorophenyl)amino]-2-methylbutan-2-ol

(19). Reaction of epoxide **16** (152 mg, 0.656 mmol), 4-chloroaniline (110 mg, 0.862 mmol), and anhydrous cobalt(II) chloride (58.3 mg, 0.449 mmol), using General Procedure A at 65 °C for 33 h, gave **19** (186 mg, 79%) as a yellow oil; 1H NMR ($CDCl_3$) δ 7.78 (s, 1 H), 7.15 (br d, $J = 8.9$ Hz, 2 H), 6.61 (br d, $J = 8.9$ Hz, 2 H), 4.32-4.16 (m, 2 H), 3.92 (br t, $J = 5.9$ Hz, 1 H), 3.17 (dd, $J = 13.4, 7.2$ Hz, 1 H), 3.12 (dd, $J = 13.3, 5.7$ Hz, 1 H), 2.12 (ddd, $J = 13.8, 9.6, 6.1$ Hz, 1 H), 1.98 (ddd, $J = 13.7, 9.8, 6.5$ Hz, 1 H), 1.88 (s, 1 H), 1.36 (s, 3 H); HRESIMS calcd for $C_{14}H_{16}Cl_2N_4NaO_3$ m/z $[M + Na]^+$ 385.0441, 383.0465, 381.0492, found 385.0429, 383.0453, 381.0482.

4-Chloro-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-

yl)methyl]aniline (20). Reaction of alcohol **19** (184 mg, 0.512 mmol) and NaH (32.0 mg, 0.800 mmol), using General Procedure B at 20 °C for 3.5 h, gave **20** (25 mg, 15%) as a yellow-orange solid: mp (CH_2Cl_2 /pentane) 179-182 °C; 1H NMR $[(CD_3)_2SO]$ δ 8.06 (s, 1 H), 7.07 (br d, $J = 8.9$ Hz, 2 H), 6.71 (br d, $J = 8.9$ Hz, 2 H), 6.03 (br t, $J = 6.5$ Hz, 1 H), 4.15 (ddd, $J = 13.1, 5.9, 4.7$ Hz, 1 H), 4.07 (ddd, $J = 13.0, 9.7, 5.4$ Hz, 1 H), 3.36 (d, $J = 6.5$ Hz, 2 H), 2.24 (ddd, $J = 14.2, 9.8, 6.0$ Hz, 1 H), 2.07 (dt, $J = 14.4, 4.9$ Hz, 1 H), 1.39 (s, 3 H). Anal. ($C_{14}H_{15}ClN_4O_3$) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-[(4-fluorophenyl)amino]-2-methylbutan-2-ol (21). Reaction of epoxide **16** (150 mg, 0.648 mmol), 4-fluoroaniline (85 μ L, 0.897 mmol), and anhydrous cobalt(II) chloride (49.3 mg, 0.380 mmol), using General Procedure A at 67 °C for 37 h, gave **21** (189 mg, 85%) as a yellow oil; ¹H NMR (CDCl₃) δ 7.79 (s, 1 H), 6.91 (br dd, J = 8.9, 8.5 Hz, 2 H), 6.64 (br dd, J = 9.0, 4.3 Hz, 2 H), 4.32-4.16 (m, 2 H), 3.79 (br s, 1 H), 3.15 (d, J = 13.0 Hz, 1 H), 3.11 (d, J = 13.1 Hz, 1 H), 2.12 (ddd, J = 13.7, 9.9, 5.9 Hz, 1 H), 2.02 (br s, 1 H), 1.98 (ddd, J = 13.7, 10.0, 6.3 Hz, 1 H), 1.36 (s, 3 H); HRESIMS calcd for C₁₄H₁₇ClFN₄O₃ m/z [M + H]⁺ 345.0943, 343.0968, found 345.0942, 343.0967.

4-Fluoro-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]aniline (22). Reaction of alcohol **21** (187 mg, 0.546 mmol) and NaH (30.0 mg, 0.750 mmol), using General Procedure B at 20 °C for 200 min, gave **22** (35 mg, 21%) as a yellow-orange solid: mp (CH₂Cl₂/pentane) 193 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 6.90 (br t, J = 8.9 Hz, 2 H), 6.69 (br dd, J = 9.1, 4.6 Hz, 2 H), 5.73 (br t, J = 6.6 Hz, 1 H), 4.15 (ddd, J = 13.0, 5.9, 4.8 Hz, 1 H), 4.07 (ddd, J = 13.1, 9.6, 5.4 Hz, 1 H), 3.33 (d, J = 6.6 Hz, 2 H), 2.26 (ddd, J = 14.4, 9.5, 6.1 Hz, 1 H), 2.07 (dt, J = 14.3, 5.0 Hz, 1 H), 1.40 (s, 3 H). Anal. (C₁₄H₁₅FN₄O₃) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-{methyl[4-(trifluoromethoxy)phenyl]amino}-butan-2-ol (23). Reaction of epoxide **13** (192 mg, 0.882 mmol), *N*-methyl-4-(trifluoromethoxy)aniline (253 mg, 1.32 mmol), and anhydrous cobalt(II) chloride (98 mg, 0.755 mmol), using General Procedure A at 65 °C for 64 h, gave **23** (170 mg, 47%) as a yellow oil; ¹H NMR (CDCl₃) δ 7.83 (s, 1 H), 7.11 (br d, J = 9.2 Hz, 2 H), 6.78 (br d, J = 9.2 Hz, 2 H), 4.34-4.24 (m, 2 H), 3.91-3.82 (m, 1 H), 3.28 (dd, J = 14.6, 9.0 Hz, 1 H), 3.21 (dd, J = 14.5, 3.9 Hz, 1 H), 2.93 (s, 3 H), 2.46 (dd, J = 2.3, 1.7 Hz, 1 H), 2.07-1.95 (m, 1 H), 1.95-1.83 (m, 1 H); APCI MS calcd for C₁₅H₁₇ClF₃N₄O₄ m/z [M + H]⁺ 411, 409, found 411, 409.

***N*-Methyl-*N*-[(2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-(trifluoromethoxy)aniline (24).** Reaction of alcohol **23** (169 mg, 0.413 mmol) and NaH (108 mg, 2.70 mmol), using General Procedure B at 20 °C for 2 h, gave **24** (98 mg, 63%) as a pale yellow solid: mp 141-143 °C; ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 7.16 (br d, J = 8.5 Hz, 2 H), 6.82 (br d, J = 9.3 Hz, 2 H), 4.81-4.71 (m, 1 H), 4.14 (ddd, J = 12.6, 5.8, 2.4 Hz, 1 H), 4.03 (ddd, J = 12.4, 11.5, 5.0 Hz, 1 H), 3.77 (dd, J = 15.6, 4.0 Hz, 1 H), 3.67 (dd, J = 15.6, 7.6 Hz, 1 H), 3.01 (s, 3 H), 2.31-2.23 (m, 1 H), 2.10-1.97 (m, 1 H). Anal. (C₁₅H₁₅F₃N₄O₄) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-2-methyl-1-{methyl[4-(trifluoromethoxy)phenyl]amino}butan-2-ol (25). Reaction of epoxide **16** (400 mg, 1.73 mmol), *N*-methyl-4-(trifluoromethoxy)aniline (305 μ L, 2.07 mmol), and anhydrous cobalt(II) chloride (50.3 mg, 0.387 mmol), using General Procedure A at 67 °C for 45 h, gave **25** (589 mg, 81%) as a yellow oil; ¹H NMR (CDCl₃) δ 7.78 (s, 1 H), 7.10 (br d, J = 9.2 Hz, 2 H), 6.83 (br d, J = 9.3 Hz, 2 H), 4.29 (ddd, J = 14.3, 9.9, 6.3 Hz, 1 H), 4.24 (ddd, J = 14.2, 9.6, 6.5 Hz, 1 H), 3.39 (d, J = 15.2 Hz, 1 H), 3.28 (d, J = 15.3 Hz, 1 H), 3.04 (s, 3 H), 2.07 (ddd, J = 13.6, 9.8, 6.1 Hz, 1 H), 1.97 (ddd, J = 13.6, 9.8, 6.4 Hz, 1 H), 1.89 (s, 1 H), 1.35 (s, 3 H); HRESIMS calcd for C₁₆H₁₈ClF₃N₄NaO₄ m/z [M + Na]⁺ 447.0837, 445.0861, found 447.0829, 445.0851.

***N*-Methyl-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-(trifluoromethoxy)aniline (26).** Reaction of alcohol **25** (585 mg, 1.38 mmol) and NaH (87 mg, 2.18 mmol), using General Procedure B for 4 h, gave **26** (247 mg, 46%) as a light yellow solid: mp (Et₂O/pentane triturate) 157-158 °C; ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 7.14 (br d, J = 8.6 Hz, 2 H), 6.87 (br d, J = 9.3 Hz, 2 H), 4.14 (ddd, J = 13.0, 5.4, 4.6 Hz, 1 H), 4.06

(ddd, $J = 13.1, 8.9, 6.6$ Hz, 1 H), 3.71 (d, $J = 16.2$ Hz, 1 H), 3.67 (d, $J = 16.3$ Hz, 1 H), 2.98 (s, 3 H), 2.22-2.09 (m, 2 H), 1.36 (s, 3 H); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$ δ 148.9, 147.2, 142.2, 138.7 (q, $J_{\text{C-F}} = 1.8$ Hz), 121.8 (2 C), 120.3 (q, $J_{\text{C-F}} = 254.0$ Hz), 117.7, 112.5 (2 C), 84.4, 59.2, 40.2, 39.4, 27.3, 21.2. Anal. ($\text{C}_{16}\text{H}_{17}\text{F}_3\text{N}_4\text{O}_4$) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-[(4-chlorophenyl)(methyl)amino]-2-methylbutan-2-ol (27). Reaction of epoxide **16** (281 mg, 1.21 mmol), 4-chloro-*N*-methylaniline (240 mg, 1.69 mmol), and anhydrous cobalt(II) chloride (101 mg, 0.778 mmol), using General Procedure A at 75 °C for 24 h, gave **27** (427 mg, 94%) as a yellow oil; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 8.55 (s, 1 H), 7.13 (br d, $J = 9.1$ Hz, 2 H), 6.78 (br d, $J = 9.2$ Hz, 2 H), 4.71 (s, 1 H), 4.23-4.13 (m, 2 H), 3.35-3.24 (m, 2 H), 2.95 (s, 3 H), 2.02-1.84 (m, 2 H), 1.13 (s, 3 H); APCI MS calcd for $\text{C}_{15}\text{H}_{18}\text{Cl}_3\text{N}_4\text{O}_3$ m/z $[\text{M} + \text{Cl}]^-$ 411, 409, 407, found 411, 409, 407.

4-Chloro-*N*-methyl-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]aniline (28). Reaction of alcohol **27** (267 mg, 0.715 mmol) and NaH (57 mg, 1.43 mmol), using General Procedure B at 55 °C for 2 h, gave **28** (102 mg, 42%) as a yellow solid: mp 183-185 °C; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 8.06 (s, 1 H), 7.17 (br d, $J = 9.0$ Hz, 2 H), 6.83 (br d, $J = 9.1$ Hz, 2 H), 4.13 (ddd, $J = 12.9, 5.3, 4.8$ Hz, 1 H), 4.06 (ddd, $J = 13.1, 8.8, 6.7$ Hz, 1 H), 3.73-3.62 (m, 2 H), 2.96 (s, 3 H), 2.20-2.05 (m, 2 H), 1.35 (s, 3 H). Anal. ($\text{C}_{15}\text{H}_{17}\text{ClN}_4\text{O}_3$) C, H, N (see Table S4).

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-1-[(4-fluorophenyl)(methyl)amino]-2-methylbutan-2-ol (29). Reaction of epoxide **16** (378 mg, 1.63 mmol), 4-fluoro-*N*-methylaniline (285 mg, 2.28 mmol), and anhydrous cobalt(II) chloride (111 mg, 0.855 mmol), using General Procedure A at 75 °C for 24 h, gave **29** (565 mg, 97%) as a yellow oil; ^1H NMR (CDCl_3) δ 7.77 (s, 1 H), 6.96 (br dd, $J = 9.3, 8.2$ Hz, 2 H), 6.82 (br dd, $J = 9.3, 4.3$ Hz, 2 H), 4.33-4.18 (m, 2 H), 3.32 (d, $J = 15.2$ Hz, 1 H), 3.23 (d, $J = 15.1$ Hz, 1 H), 2.99 (s, 3 H), 2.11-2.01 (m, 2 H), 2.01-1.91 (m, 1 H), 1.34 (s, 3 H); APCI MS calcd for $\text{C}_{15}\text{H}_{19}\text{ClFN}_4\text{O}_3$ m/z $[\text{M} + \text{H}]^+$ 359, 357, found 359, 357.

4-Fluoro-*N*-methyl-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]aniline (30). Reaction of alcohol **29** (563 mg, 1.58 mmol) and NaH (101 mg, 2.53 mmol), using General Procedure B at 50 °C for 3 h, gave **30** (137 mg, 27%) as a yellow solid: mp 149-151 °C; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 8.06 (s, 1 H), 7.00 (br dd, $J = 9.1, 8.7$ Hz, 2 H), 6.82 (br dd, $J = 9.3, 4.4$ Hz, 2 H), 4.14 (ddd, $J = 13.0, 5.7, 4.3$ Hz, 1 H), 4.06 (ddd, $J = 13.0, 9.6, 5.9$ Hz, 1 H), 3.65 (d, $J = 16.1$ Hz, 1 H), 3.60 (d, $J = 16.2$ Hz, 1 H), 2.94 (s, 3 H), 2.23-2.07 (m, 2 H), 1.36 (s, 3 H). Anal. ($\text{C}_{15}\text{H}_{17}\text{FN}_4\text{O}_3$) C, H, N (see Table S4).

***N*-[6-(Trifluoromethyl)pyridin-3-yl]formamide (32).** A mixture of formic acid (1.25 mL, 33.1 mmol) and acetic anhydride (2.5 mL, 26.5 mmol) was stirred at 50 °C for 2 h, then cooled to 20 °C and added to a solution of 6-(trifluoromethyl)pyridin-3-amine (**31**) (821 mg, 5.06 mmol) in anhydrous THF (2 mL) under N_2 , rinsing in residues with additional anhydrous THF (2 mL). The mixture was stirred at 20 °C for 23 h and then added to ice/aq NaHCO_3 (100 mL) and extracted with CH_2Cl_2 (6 x 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-0.5% MeOH/ CH_2Cl_2 first gave foreruns, and then further elution with 0.5-1% MeOH/ CH_2Cl_2 gave **32** (930 mg, 97%) as a white solid: mp (CH_2Cl_2 /hexane) 110-113 °C; ^1H NMR (CDCl_3) δ 8.67 (d, $J = 2.4$ Hz, 1 H), 8.51 (d, $J = 0.9$ Hz, 1 H), 8.44 (dd, $J = 8.6, 2.3$ Hz, 1 H), 7.70 (d, $J = 8.6$ Hz, 1 H), 7.45 (br s, 1 H). Anal. ($\text{C}_7\text{H}_5\text{F}_3\text{N}_2\text{O}$) C, H, N (see Table S4).

***N*-Methyl-6-(trifluoromethyl)pyridin-3-amine (33).** Borane-dimethyl sulfide complex (5.4 mL of 2 M solution in THF, 10.8 mmol) was added dropwise to a stirred solution of formamide **32** (800 mg, 4.21 mmol) in anhydrous THF (3 mL) under N₂ at 0 °C. The mixture was stirred at 20 °C for 30 min and then at 65 °C for 3.5 h, before being recooled to 0 °C. MeOH (2.2 mL) was added, and the mixture was stirred at 0-20 °C for 22 h, then saturated with anhydrous HCl gas and stirred at 65 °C for 1 h. After cooling to 20 °C, MeOH (20 mL) was added, and the solvents were removed under reduced pressure (at 30 °C). The oily residue was treated with 2 M NaOH (30 mL) and water (20 mL) and extracted with CH₂Cl₂ (4 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with CH₂Cl₂ first gave foreruns and then **33**^{S6} (533 mg, 72%) as a colourless oil; ¹H NMR (CDCl₃) δ 8.06 (d, *J* = 2.8 Hz, 1 H), 7.47 (d, *J* = 8.6 Hz, 1 H), 6.88 (dd, *J* = 8.6, 2.8 Hz, 1 H), 4.16 (br s, 1 H), 2.91 (d, *J* = 5.2 Hz, 3 H); HRESIMS calcd for C₇H₈F₃N₂ *m/z* [M + H]⁺ 177.0634, found 177.0631.

4-(2-Chloro-4-nitro-1*H*-imidazol-1-yl)-2-methyl-1-{methyl[6-(trifluoromethyl)pyridin-3-yl]amino}butan-2-ol (34). Reaction of epoxide **16** (293 mg, 1.26 mmol), methylaminopyridine **33** (536 mg, 3.04 mmol), and anhydrous cobalt(II) chloride (125 mg, 0.963 mmol), using General Procedure A at 70 °C for 3 d, gave **34** (89 mg, 17%) as a yellow oil; ¹H NMR (CDCl₃) δ 8.31 (d, *J* = 3.0 Hz, 1 H), 7.80 (s, 1 H), 7.49 (d, *J* = 8.9 Hz, 1 H), 7.16 (dd, *J* = 8.8, 2.9 Hz, 1 H), 4.35-4.19 (m, 2 H), 3.52 (d, *J* = 15.4 Hz, 1 H), 3.39 (d, *J* = 15.4 Hz, 1 H), 3.14 (s, 3 H), 2.15-2.05 (m, 1 H), 2.04-1.93 (m, 1 H), 1.86 (s, 1 H), 1.38 (s, 3 H); APCI MS calcd for C₁₅H₁₇Cl₂F₃N₅O₃ *m/z* [M + Cl]⁻ 444, 442, found 444, 442.

***N*-Methyl-*N*-[(7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-6-(trifluoromethyl)pyridin-3-amine (35).** Reaction of alcohol **34** (103 mg, 0.253 mmol) and NaH (15 mg, 0.375 mmol), using General Procedure B at 70 °C for 2 h, gave **35** (44 mg, 47%) as a pale yellow solid: mp (Et₂O/CH₂Cl₂/pentane triturate) 106-109 °C; ¹H NMR (CDCl₃) δ 8.22 (d, *J* = 3.0 Hz, 1 H), 7.52 (d, *J* = 8.8 Hz, 1 H), 7.45 (s, 1 H), 7.11 (dd, *J* = 8.9, 3.0 Hz, 1 H), 4.19-4.06 (m, 2 H), 3.79 (d, *J* = 16.1 Hz, 1 H), 3.74 (d, *J* = 16.1 Hz, 1 H), 3.18 (s, 3 H), 2.30 (ddd, *J* = 14.2, 9.9, 8.1 Hz, 1 H), 2.05 (ddd, *J* = 14.2, 4.3, 3.3 Hz, 1 H), 1.48 (s, 3 H); HRESIMS calcd for C₁₅H₁₇F₃N₅O₃ *m/z* [M + H]⁺ 372.1278, found 372.1271; HPLC purity: 97.8%.

Synthesis of benzylamine 40 (Scheme 2A)

1-Azido-4-(2-chloro-4-nitro-1*H*-imidazol-1-yl)-2-methylbutan-2-ol (36). A mixture of epoxide **16** (281 mg, 1.21 mmol), sodium azide (332 mg, 5.11 mmol), and *N*-cetyl-*N,N,N*-trimethylammonium bromide (446 mg, 1.22 mmol) in MeOH (10 mL) was stirred at 20 °C for 45 min and then at 40 °C for 17 h. The resulting cooled mixture was treated with excess NaHCO₃ (0.15 g, 1.79 mmol), then added to brine (50 mL), and extracted with CH₂Cl₂ (5 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-0.25% MeOH/CH₂Cl₂ first gave foreruns and then further elution with 0.25% MeOH/CH₂Cl₂ gave **36** (242 mg, 73%) as a colourless oil; ¹H NMR (CDCl₃) δ 7.80 (s, 1 H), 4.28-4.13 (m, 2 H), 3.39 (d, *J* = 12.2 Hz, 1 H), 3.34 (d, *J* = 12.2 Hz, 1 H), 2.06 (ddd, *J* = 13.7, 9.5, 6.4 Hz, 1 H), 1.94 (s, 1 H), 1.92 (ddd, *J* = 13.8, 9.5, 6.7 Hz, 1 H), 1.32 (s, 3 H); HRESIMS calcd for C₈H₁₂ClN₆O₃ *m/z* [M + H]⁺ 277.0627, 275.0654, found 277.0632, 275.0648.

7-(Azidomethyl)-7-methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (37). Reaction of alcohol **36** (2.42 g, 8.81 mmol) and NaH (508 mg, 12.7 mmol), using General Procedure B for 2.5 h, gave **37** (1.48 g, 70%) as a cream solid: mp (CH₂Cl₂/pentane) 138-139

°C; ¹H NMR (CDCl₃) δ 7.45 (s, 1 H), 4.15 (ddd, *J* = 12.7, 6.2, 4.9 Hz, 1 H), 4.09 (ddd, *J* = 12.8, 9.3, 5.5 Hz, 1 H), 3.59 (d, *J* = 12.9 Hz, 1 H), 3.47 (d, *J* = 12.9 Hz, 1 H), 2.39 (ddd, *J* = 14.4, 9.2, 6.2 Hz, 1 H), 2.05 (dt, *J* = 14.4, 5.1 Hz, 1 H), 1.49 (s, 3 H). Anal. (C₈H₁₀N₆O₃) C, H, N (see Table S4).

1-(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methanamine (38) and *N*-[(7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-1,1,1-triphenyl-λ⁵-phosphanimine (39). Triphenylphosphine (605 mg, 2.31 mmol) was added to a suspension of azide **37** (181 mg, 0.760 mmol) in dioxane (13.5 mL) and water (1.5 mL) at 12 °C. The mixture was stirred at 20 °C for 24 h in a sealed vial, then transferred to a flask (in MeOH/CH₂Cl₂) and evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0-5% MeOH/CH₂Cl₂ first gave foreruns, and then further elution with 5-6% MeOH/CH₂Cl₂ gave **38** (78 mg, 48%) as a light yellow solid (following Et₂O trituration): mp 118-120 °C; ¹H NMR [(CD₃)₂SO] δ 8.05 (s, 1 H), 4.11 (dt, *J* = 13.0, 5.9 Hz, 1 H), 4.04 (ddd, *J* = 13.1, 8.4, 5.5 Hz, 1 H), 2.76 (d, *J* = 13.5 Hz, 1 H), 2.71 (d, *J* = 13.5 Hz, 1 H), 2.22 (ddd, *J* = 14.4, 8.4, 6.0 Hz, 1 H), 1.97 (dt, *J* = 14.4, 5.6 Hz, 1 H), 1.79 (br s, 2 H), 1.32 (s, 3 H); HRESIMS calcd for C₈H₁₂N₄NaO₃ *m/z* [M + Na]⁺ 235.0802, found 235.0791.

Further elution of the above column with 6-7% MeOH/CH₂Cl₂ gave a mixture of **38** and **39** (24 mg) and then elution with 10% MeOH/CH₂Cl₂ containing 1% concd NH₃ gave crude **39** (114 mg, 32%) as a light orange solid (following Et₂O/pentane trituration): mp 135 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.03 (s, 1 H), 7.92-7.71 (m, 15 H), 4.08 (dt, *J* = 13.1, 5.6 Hz, 1 H), 4.00 (ddd, *J* = 13.2, 8.8, 5.4 Hz, 1 H), 3.27 (d, ³*J*_{H-P} = 10.9 Hz, 2 H), 2.20 (ddd, *J* = 14.4, 8.6, 6.1 Hz, 1 H), 1.93 (dt, *J* = 14.4, 5.2 Hz, 1 H), 1.20 (s, 3 H); HRESIMS calcd for C₂₆H₂₆N₄O₃P *m/z* [M + H]⁺ 473.1737, found 473.1735.

1-(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)-*N*-[4-(trifluoromethoxy)benzyl]methanamine (40). 4-(Trifluoromethoxy)benzaldehyde (60 μL, 0.420 mmol) was added to a mixture of amine **38** (26.5 mg, 0.125 mmol) and AcOH (25 μL, 0.437 mmol) in anhydrous DMF (1.8 mL) under N₂. The mixture was stirred at 20 °C for 20 min and then cooled to 0 °C. Sodium cyanoborohydride (30 mg, 0.477 mmol) was added and the mixture was quickly degassed and resealed under N₂, and then stirred at 20 °C for 21 h. The resulting mixture was rapidly cooled (CO₂/acetone), quenched with ice/aqueous sodium carbonate (10 mL), added to brine (40 mL), and extracted with CH₂Cl₂ (5 x 50 mL) and EtOAc (50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-0.4% MeOH/CH₂Cl₂ first gave foreruns, and then further elution with 0.5-0.6% MeOH/CH₂Cl₂ gave **40** (24 mg, 50%) as a light yellow solid: mp (CH₂Cl₂/pentane) 70-71 °C; ¹H NMR (CDCl₃) δ 7.42 (s, 1 H), 7.33 (br d, *J* = 8.6 Hz, 2 H), 7.17 (br d, *J* = 7.9 Hz, 2 H), 4.06 (dd, *J* = 8.1, 4.9 Hz, 2 H), 3.84 (s, 2 H), 2.90 (d, *J* = 12.7 Hz, 1 H), 2.78 (d, *J* = 12.7 Hz, 1 H), 2.55 (dt, *J* = 14.6, 8.0 Hz, 1 H), 1.95 (dt, *J* = 14.4, 4.9 Hz, 1 H), 1.45 (s, 3 H); ¹³C NMR (CDCl₃) δ 148.5, 147.9, 144.0, 138.8, 129.5 (2 C), 121.2 (2 C), 120.7 (q, *J*_{C-F} = 257.3 Hz), 114.5, 81.9, 56.8, 53.3, 40.0, 28.4, 22.7; HRESIMS calcd for C₁₆H₁₈F₃N₄O₄ *m/z* [M + H]⁺ 387.1275, found 387.1276; HPLC purity: 97.4%.

Syntheses of amides 43-48 (Scheme 2B)

7-(Azidomethyl)-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (42). Diethyl azodicarboxylate (0.175 mL, 1.13 mmol) was added dropwise to a stirred solution of (2-nitro-

6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methanol^{S1} (**41**) (200 mg, 1.00 mmol) and triphenylphosphine (291 mg, 1.11 mmol) in anhydrous DMF (2 mL) under N₂ at 0 °C. The mixture was stirred at 0 °C for 30 min and then diphenylphosphoryl azide (0.250 mL, 1.16 mmol) was added dropwise. After being stirred at 0 °C for 1 h and then at 20 °C for 44 h, the mixture was concentrated under reduced pressure (at 30 °C) to give an oil, which was chromatographed on silica gel. Elution with 0-50% EtOAc/petroleum ether first gave foreruns, and then further elution with 50-75% EtOAc/petroleum ether gave the crude product, which was further purified by chromatography on silica gel. Elution with 0-1% EtOAc/CH₂Cl₂ first gave foreruns, and then further elution with 1-3% EtOAc/CH₂Cl₂ gave **42** (187 mg, 83%) as a white solid: mp (CH₂Cl₂/hexane) 98-101 °C; ¹H NMR (CDCl₃) δ 7.44 (s, 1 H), 4.59-4.49 (m, 1 H), 4.18 (ddd, *J* = 12.5, 5.4, 3.2 Hz, 1 H), 4.10 (ddd, *J* = 12.5, 10.5, 6.0 Hz, 1 H), 3.68 (dd, *J* = 13.3, 4.9 Hz, 1 H), 3.64 (dd, *J* = 13.2, 4.9 Hz, 1 H), 2.37-2.22 (m, 2 H). Anal. (C₇H₈N₆O₃) C, H, N (see Table S4).

***N*-[(2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-(trifluoromethoxy)benzamide (43)**. Reaction of azide **42** (40.7 mg, 0.182 mmol) with 4-(trifluoromethoxy)benzoyl chloride (60 μL, 0.381 mmol) and triphenylphosphine (61.0 mg, 0.233 mmol), using General Procedure C for 130 min, gave **43** (35.5 mg, 51%) as a cream solid: mp (Et₂O/pentane triturate) 89-91 °C (dec); ¹H NMR (CDCl₃) δ 7.85 (br d, *J* = 8.8 Hz, 2 H), 7.44 (s, 1 H), 7.29 (br d, *J* = 8.8 Hz, 2 H), 6.82 (br t, *J* = 5.9 Hz, 1 H), 4.70-4.60 (m, 1 H), 4.22-4.01 (m, 3 H), 3.69 (ddd, *J* = 14.5, 7.1, 5.6 Hz, 1 H), 2.42-2.32 (m, 1 H), 2.27-2.12 (m, 1 H). Anal. (C₁₅H₁₃F₃N₄O₅·0.5H₂O) C, H, N (see Table S4). HPLC purity: 99.8%.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-(trifluoromethoxy)benzamide (44)**. Reaction of azide **37** (120 mg, 0.504 mmol) with 4-(trifluoromethoxy)benzoyl chloride (160 μL, 1.02 mmol) and triphenylphosphine (161 mg, 0.614 mmol), using General Procedure C, gave **44** (148 mg, 73%) as a pale yellow solid: mp (Et₂O/pentane triturate) 99-100 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.85 (br t, *J* = 6.0 Hz, 1 H), 8.08 (s, 1 H), 8.01 (br d, *J* = 8.6 Hz, 2 H), 7.47 (br d, *J* = 8.3 Hz, 2 H), 4.21 (dt, *J* = 13.1, 5.3 Hz, 1 H), 4.07 (ddd, *J* = 13.0, 8.1, 5.4 Hz, 1 H), 3.64 (dd, *J* = 14.1, 5.9 Hz, 1 H), 3.59 (dd, *J* = 14.1, 6.2 Hz, 1 H), 2.18 (ddd, *J* = 14.3, 8.2, 6.1 Hz, 1 H), 2.08 (dt, *J* = 14.3, 5.2 Hz, 1 H), 1.39 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 165.9, 150.3, 147.3, 142.2, 133.3, 129.8 (2 C), 120.6 (2 C), 119.9 (q, *J*_{C-F} = 257.1 Hz), 117.7, 81.8, 46.0, 39.5, 27.4, 22.1. Anal. (C₁₆H₁₅F₃N₄O₅·0.5H₂O) C, H, N (see Table S4). HPLC purity: 98.7%.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-3-(trifluoromethoxy)benzamide (45)**. Propane-1,3-dithiol (106 μL, 1.06 mmol) was added to a mixture of azide **37** (126 mg, 0.529 mmol) and triethylamine (150 μL, 1.08 mmol) in anhydrous MeOH (2.5 mL) under N₂ at 15 °C. After being stirred at 20 °C for 45 min, the mixture was diluted with anhydrous CH₂Cl₂ (2 mL), and stirring was continued for 7 h. Further triethylamine (230 μL, 1.65 mmol) and propane-1,3-dithiol (160 μL, 1.59 mmol) were added, and the mixture was stirred at 20 °C for 4 h. The resulting mixture was then added to excess petroleum ether (100 mL) above the top of a silica gel column (20 g packed in petroleum ether), rinsing on with minimal 10% MeOH/CH₂Cl₂. Elution with 0-75% CH₂Cl₂/petroleum ether and 0-3% MeOH/CH₂Cl₂ first gave foreruns, and then further elution with 3-5% MeOH/CH₂Cl₂ gave crude amine **38** (93 mg, 83%) as a yellow solid, which was dissolved in anhydrous DMF (2 mL), sealed under N₂, and cooled in an ice bath. *N,N*-Diisopropylethylamine (185 μL, 1.06 mmol) and 3-(trifluoromethoxy)benzoyl chloride (105 mg, 0.468 mmol) were added, and the mixture was stirred at 20 °C for 19 h. The reaction was quenched with ice (5 mL), then added to brine (40 mL) and extracted with CH₂Cl₂ (5 x 50

mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-0.5% MeOH/CH₂Cl₂ first gave foreruns, and then further elution with 0.5-0.67% MeOH/CH₂Cl₂ gave **45** (80 mg, 46%) as a cream solid: mp (Et₂O/pentane triturate) 160-161 °C; ¹H NMR [(CD₃)₂SO] δ 8.91 (br t, *J* = 6.2 Hz, 1 H), 8.08 (s, 1 H), 7.94 (dt, *J* = 7.7, 1.2 Hz, 1 H), 7.86-7.82 (m, 1 H), 7.63 (t, *J* = 7.9 Hz, 1 H), 7.59-7.54 (m, 1 H), 4.21 (dt, *J* = 13.0, 5.6 Hz, 1 H), 4.07 (ddd, *J* = 13.1, 8.7, 5.6 Hz, 1 H), 3.65 (dd, *J* = 14.0, 6.4 Hz, 1 H), 3.60 (dd, *J* = 14.0, 6.2 Hz, 1 H), 2.18 (ddd, *J* = 14.5, 8.6, 5.9 Hz, 1 H), 2.09 (dt, *J* = 14.4, 5.4 Hz, 1 H), 1.40 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 165.5, 148.2 (q, *J*_{C-F} = 1.9 Hz), 147.3, 142.2, 136.3, 130.5, 126.6, 123.9, 120.04 (q, *J*_{C-F} = 256.8 Hz), 119.97, 117.7, 81.8, 46.1, 39.5, 27.4, 22.1. Anal. (C₁₆H₁₅F₃N₄O₅) C, H, N (see Table S4).

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-2-(trifluoromethoxy)benzamide (46)**. Reaction of azide **37** (119 mg, 0.500 mmol) with 2-(trifluoromethoxy)benzoyl chloride (230 mg, 1.02 mmol) and triphenylphosphine (161 mg, 0.614 mmol), using General Procedure C for 90 min, gave **46** (163 mg, 82%) as a cream foam (after trituration in Et₂O/pentane and drying under vacuum); ¹H NMR (CDCl₃) δ 7.89 (dd, *J* = 7.8, 1.8 Hz, 1 H), 7.54 (ddd, *J* = 8.2, 7.6, 1.7 Hz, 1 H), 7.45 (s, 1 H), 7.41 (td, *J* = 7.6, 1.0 Hz, 1 H), 7.33 (br dd, *J* = 8.3, 1.2 Hz, 1 H), 6.85 (br t, *J* = 5.9 Hz, 1 H), 4.21 (ddd, *J* = 12.8, 6.2, 3.8 Hz, 1 H), 4.11 (ddd, *J* = 12.7, 10.4, 5.4 Hz, 1 H), 3.86 (dd, *J* = 14.3, 6.7 Hz, 1 H), 3.81 (dd, *J* = 14.4, 6.2 Hz, 1 H), 2.33 (ddd, *J* = 14.6, 10.3, 6.2 Hz, 1 H), 2.12 (ddd, *J* = 14.6, 5.3, 3.8 Hz, 1 H), 1.51 (s, 3 H). Anal. (C₁₆H₁₅F₃N₄O₅·0.25Et₂O) C, H, N (see Table S4). HPLC purity: 99.7%.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-2-[4-(trifluoromethoxy)phenyl]acetamide (47)**. Reaction of azide **37** (121 mg, 0.508 mmol) with [4-(trifluoromethoxy)phenyl]acetyl chloride^{S7} (252 mg, 1.06 mmol) and triphenylphosphine (159 mg, 0.606 mmol), using General Procedure C, gave **47** (176 mg, 84%) as a cream solid: mp (CH₂Cl₂/pentane) 139-141 °C; ¹H NMR [(CD₃)₂SO] δ 8.43 (br t, *J* = 6.1 Hz, 1 H), 8.06 (s, 1 H), 7.38 (br d, *J* = 8.7 Hz, 2 H), 7.28 (br d, *J* = 7.9 Hz, 2 H), 4.14 (dt, *J* = 13.1, 5.5 Hz, 1 H), 4.04 (ddd, *J* = 13.1, 8.6, 5.6 Hz, 1 H), 3.56 (d, *J* = 14.6 Hz, 1 H), 3.52 (d, *J* = 14.5 Hz, 1 H), 3.43 (dd, *J* = 14.1, 6.2 Hz, 1 H), 3.38 (dd, *J* = 14.2, 6.2 Hz, 1 H), 2.07 (ddd, *J* = 14.5, 8.6, 5.9 Hz, 1 H), 1.99 (dt, *J* = 14.4, 5.5 Hz, 1 H), 1.30 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 170.5, 147.2, 147.0 (q, *J*_{C-F} = 1.6 Hz), 142.2, 135.8, 130.8 (2 C), 120.8 (2 C), 120.1 (q, *J*_{C-F} = 255.8 Hz), 117.7, 81.6, 45.5, 41.2, 39.5, 27.2, 21.8; HRESIMS calcd for C₁₇H₁₈F₃N₄O₅ *m/z* [M + H]⁺ 415.1224, found 415.1232; HPLC purity: 100%.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-2-[4-(trifluoromethoxy)phenoxy]acetamide (48)**. Reaction of azide **37** (139 mg, 0.584 mmol) with [4-(trifluoromethoxy)phenoxy]acetyl chloride (312 mg, 1.23 mmol) and triphenylphosphine (186 mg, 0.709 mmol), using General Procedure C for 95 min, gave **48** (200 mg, 80%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 198-200 °C; ¹H NMR (CDCl₃) δ 7.44 (s, 1 H), 7.18 (br d, *J* = 9.1 Hz, 2 H), 6.99 (br t, *J* = 6.3 Hz, 1 H), 6.95 (br d, *J* = 9.2 Hz, 2 H), 4.56 (d, *J* = 15.2 Hz, 1 H), 4.52 (d, *J* = 15.2 Hz, 1 H), 4.14 (ddd, *J* = 12.8, 6.5, 3.5 Hz, 1 H), 4.08 (ddd, *J* = 12.8, 10.5, 5.3 Hz, 1 H), 3.73 (dd, *J* = 14.4, 6.7 Hz, 1 H), 3.68 (dd, *J* = 14.4, 6.5 Hz, 1 H), 2.17 (ddd, *J* = 14.5, 10.3, 6.5 Hz, 1 H), 2.05 (ddd, *J* = 14.5, 5.2, 3.5 Hz, 1 H), 1.43 (s, 3 H); HRESIMS calcd for C₁₇H₁₈F₃N₄O₆ *m/z* [M + H]⁺ 431.1173, found 431.1186; HPLC purity: 100%.

Syntheses of ureas 49-53 (Scheme 2C and 2D)

1-[(2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl]-3-[4-(trifluoromethoxy)phenyl]urea (49) and 1,3-bis[(2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl]urea (50). Reaction of azide **42** (137 mg, 0.611 mmol) with 4-(trifluoromethoxy)aniline (250 μ L, 1.86 mmol), triphenylphosphine (282 mg, 1.08 mmol) and triethylammonium bicarbonate (1 mL of \sim 2 M, \sim 2.0 mmol), using General Procedure D, gave (via chromatography on silica gel, eluting with 1% MeOH/CH₂Cl₂) **49** (41 mg, 17%) as a light yellow solid: mp (Et₂O/pentane triturate) 126 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.82 (br s, 1 H), 8.07 (s, 1 H), 7.49 (br d, J = 9.1 Hz, 2 H), 7.23 (br d, J = 8.4 Hz, 2 H), 6.55 (br t, J = 5.9 Hz, 1 H), 4.63-4.53 (m, 1 H), 4.14 (ddd, J = 12.5, 5.8, 2.6 Hz, 1 H), 4.05 (ddd, J = 12.5, 11.3, 5.0 Hz, 1 H), 3.52 (ddd, J = 14.3, 6.0, 4.5 Hz, 1 H), 3.43 (dt, J = 14.3, 6.2 Hz, 1 H), 2.28-2.14 (m, 1 H), 2.07-1.90 (m, 1 H); ¹³C NMR [(CD₃)₂SO] δ 155.1, 147.9, 142.1 (q, J_{C-F} = 1.6 Hz), 142.0, 139.6, 121.6 (2 C), 120.2 (q, J_{C-F} = 254.8 Hz), 118.7 (2 C), 117.8, 77.3, 42.1, 41.7, 23.4. Anal. (C₁₅H₁₄F₃N₅O₅) C, H, N (see Table S4).

Further elution of the silica gel column with 10% MeOH/CH₂Cl₂ gave **50** (39 mg, 15%) as a yellow solid: mp (Et₂O/pentane triturate) 172 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 2 H), 6.40 (br t, J = 6.0 Hz, 2 H), 4.55-4.44 (m, 2 H), 4.13 (ddd, J = 12.6, 5.7, 2.5 Hz, 2 H), 4.03 (ddd, J = 12.4, 11.3, 5.0 Hz, 2 H), 3.43 (ddd, J = 14.4, 5.9, 4.9 Hz, 2 H), 3.37 (ddd, J = 14.5, 8.6, 6.1 Hz, 2 H), 2.23-2.11 (m, 2 H), 2.02-1.87 (m, 2 H); HRESIMS calcd for C₁₅H₁₈N₈NaO₇ m/z [M + Na]⁺ 445.1191, found 445.1182.

1-[(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl]-3-[4-(trifluoromethoxy)phenyl]urea (51) and 1,3-bis[(7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl]urea (52). Reaction of azide **37** (180 mg, 0.756 mmol) with 4-(trifluoromethoxy)aniline (135 μ L, 1.01 mmol), triphenylphosphine (350 mg, 1.33 mmol) and triethylammonium bicarbonate (1 mL of \sim 2 M, \sim 2.0 mmol), using General Procedure D, gave (via chromatography on silica gel, eluting with 1.5% MeOH/CH₂Cl₂) **51** (45 mg, 14%) as a pale yellow solid: mp (Et₂O/pentane) 161-163 °C; ¹H NMR [(CD₃)₂SO] δ 8.78 (br s, 1 H), 8.08 (s, 1 H), 7.48 (br d, J = 9.1 Hz, 2 H), 7.23 (br d, J = 8.3 Hz, 2 H), 6.55 (br t, J = 6.2 Hz, 1 H), 4.19 (dt, J = 13.0, 5.4 Hz, 1 H), 4.07 (ddd, J = 13.1, 9.1, 5.6 Hz, 1 H), 3.45 (d, J = 6.2 Hz, 2 H), 2.14 (ddd, J = 14.5, 9.0, 5.9 Hz, 1 H), 2.05 (dt, J = 14.5, 5.3 Hz, 1 H), 1.36 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 155.2, 147.2, 142.2, 142.1 (q, J_{C-F} = 1.6 Hz), 139.5, 121.7 (2 C), 120.2 (q, J_{C-F} = 255.3 Hz), 118.7 (2 C), 117.7, 82.0, 46.1, 39.5, 27.2, 21.5. Anal. (C₁₆H₁₆F₃N₅O₅) C, H, N (see Table S4).

Further elution of the silica gel column with 10% MeOH/CH₂Cl₂ gave **52** (57 mg, 17%) as a light yellow solid: mp (MeOH/CH₂Cl₂/hexane) 217 °C (dec); ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 2 H), 6.36 (br t, J = 6.2 Hz, 2 H), 4.17 (dt, J = 13.0, 5.5 Hz, 2 H), 4.05 (ddd, J = 13.1, 8.9, 5.6 Hz, 2 H), 3.36 (br d, J = 6.3 Hz, 4 H), 2.09 (ddd, J = 14.4, 8.8, 5.9 Hz, 2 H), 2.00 (dt, J = 14.4, 5.3 Hz, 2 H), 1.31 (s, 6 H); HRESIMS calcd for C₁₇H₂₂N₈NaO₇ m/z [M + Na]⁺ 473.1504, found 473.1488.

1-[(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl]-3-[4-(trifluoromethoxy)benzyl]urea (53). 1-(Isocyanatomethyl)-4-(trifluoromethoxy)benzene^{S8} (0.11 mL, 0.66 mmol) and dibutyltin diacetate (9.3 mg, 0.026 mmol) were successively added to a stirred solution of amine **38** (40.0 mg, 0.188 mmol) and DIPEA (0.10 mL, 0.574 mmol) in anhydrous DMF (2 mL) under N₂. The mixture was stirred at 20 °C for 16 h and then treated with ice-water (5 mL), added to brine (40 mL), and extracted with CH₂Cl₂ (5 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-1% MeOH/CH₂Cl₂ first

gave foreruns, and then further elution with 1-1.5% MeOH/CH₂Cl₂ gave **53** (75 mg, 93%) as a light yellow solid: mp (Et₂O/pentane triturate) 111-114 °C (dec); ¹H NMR (CDCl₃) δ 7.43 (s, 1 H), 7.34 (br d, *J* = 8.7 Hz, 2 H), 7.12 (br d, *J* = 7.9 Hz, 2 H), 6.36 (br t, *J* = 5.8 Hz, 1 H), 6.11 (br dd, *J* = 6.6, 5.8 Hz, 1 H), 4.44 (dd, *J* = 15.2, 6.4 Hz, 1 H), 4.38 (dd, *J* = 15.3, 6.1 Hz, 1 H), 4.15 (ddd, *J* = 12.7, 6.2, 3.9 Hz, 1 H), 4.03 (ddd, *J* = 12.7, 10.5, 5.4 Hz, 1 H), 3.85 (dd, *J* = 14.8, 7.7 Hz, 1 H), 3.36 (dd, *J* = 14.9, 5.3 Hz, 1 H), 2.40 (ddd, *J* = 14.7, 10.5, 6.3 Hz, 1 H), 2.09 (ddd, *J* = 14.7, 5.3, 3.9 Hz, 1 H), 1.43 (s, 3 H); HRESIMS calcd for C₁₇H₁₉F₃N₅O₅ *m/z* [M + H]⁺ 430.1333, found 430.1336; HPLC purity: 97.2%.

Synthesis of N-carbamate 55 (Scheme 2D)

4-Nitrophenyl [4-(trifluoromethoxy)benzyl] carbonate (54). 4-(Trifluoromethoxy)benzyl alcohol (0.25 mL, 1.73 mmol) was added to a solution of 4-nitrophenyl chloroformate (354 mg, 1.76 mmol) in anhydrous CH₂Cl₂ (8 mL) under N₂. The mixture was cooled to 0 °C and a solution of anhydrous pyridine (0.15 mL, 1.85 mmol) in anhydrous CH₂Cl₂ (1.5 mL) was added dropwise, with stirring. The resulting mixture was stirred at 0-20 °C for 20 h and then concentrated under reduced pressure. The residue was dissolved in EtOAc (15 mL) and washed successively with 10% citric acid (2 x 6 mL), water (15 mL), saturated aq NaHCO₃ (2 x 10 mL), and brine (10 mL). The organic phase was evaporated to dryness under reduced pressure (at 25 °C), and then the residue was diluted with benzene (20 mL) and again evaporated to dryness under reduced pressure, to give crude **54** (605 mg, 98%) as a pale yellow solid, which was used directly; ¹H NMR (CDCl₃) δ 8.28 (br d, *J* = 9.3 Hz, 2 H), 7.49 (br d, *J* = 8.7 Hz, 2 H), 7.39 (br d, *J* = 9.2 Hz, 2 H), 7.27 (br d, *J* = 7.9 Hz, 2 H), 5.30 (s, 2 H).

4-(Trifluoromethoxy)benzyl [(7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]carbamate (55). Carbonate **54** (93.5 mg crude, <0.262 mmol) was added to a mixture of amine **38** (35.2 mg, 0.166 mmol), DIPEA (30 μL, 0.172 mmol), and DMAP (7.3 mg, 0.060 mmol) in anhydrous DMF (1 mL) under N₂. The mixture was quickly degassed and resealed under N₂ and stirred at 20 °C for 44 h, then treated with ice/aq NaHCO₃ (10 mL), added to brine (40 mL), and extracted with CH₂Cl₂ (5 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 25-60% EtOAc/petroleum ether first gave foreruns, and then further elution with 60-75% EtOAc/petroleum ether gave **55** (51 mg, 71%) as a pale yellow solid: mp (CH₂Cl₂/pentane) 100-103 °C; ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 7.71 (br t, *J* = 6.4 Hz, 1 H), 7.49 (br d, *J* = 8.7 Hz, 2 H), 7.37 (br d, *J* = 8.1 Hz, 2 H), 5.09 (d, *J* = 13.0 Hz, 1 H), 5.06 (d, *J* = 13.0 Hz, 1 H), 4.15 (dt, *J* = 13.0, 5.5 Hz, 1 H), 4.04 (ddd, *J* = 13.1, 8.7, 5.6 Hz, 1 H), 3.38-3.27 (m, 2 H), 2.11 (ddd, *J* = 14.5, 8.5, 6.0 Hz, 1 H), 2.02 (dt, *J* = 14.4, 5.4 Hz, 1 H), 1.32 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 156.6, 147.8, 147.2, 142.2, 136.6, 129.6 (2 C), 121.0 (2 C), 120.0 (q, *J*_{C-F} = 255.0 Hz), 117.7, 81.4, 64.6, 47.5, 39.4, 27.2, 21.8; HRESIMS calcd for C₁₇H₁₈F₃N₄O₆ *m/z* [M + H]⁺ 431.1173, found 431.1163; HPLC purity: 98.9%.

Syntheses of sulfonamides 57 and 58 (Scheme 2E)

tert-Butyl [(7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]carbamate (56). A solution of triphenylphosphine (262 mg, 0.999 mmol) in anhydrous CH₂Cl₂ (2 x 0.75 mL) was added dropwise to a stirred mixture of azide **37** (201 mg, 0.844 mmol) and Boc-ON (246 mg, 0.999 mmol) in anhydrous CH₂Cl₂ (4 mL) under N₂ at 0 °C. The mixture was stirred at 20 °C for 24 h, then added to ice/aq NaHCO₃ (50 mL), and extracted with 10% MeOH/CH₂Cl₂ (50 mL) and CH₂Cl₂ (3 x 50 mL). The combined

extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with CH₂Cl₂ first gave foreruns and then further elution with 2% MeOH/CH₂Cl₂ gave a mixture (0.48 g), which was dried onto silica gel and chromatographed again on silica gel. Elution with 20-40% EtOAc/petroleum ether gave foreruns, and then further elution with 45% EtOAc/petroleum ether first gave a product-containing mixture (28 mg). Further elution with 45-50% EtOAc/petroleum ether gave **56** (53 mg, 20%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 217-219 °C; ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 7.20 (br t, *J* = 6.3 Hz, 1 H), 4.15 (dt, *J* = 13.1, 5.6 Hz, 1 H), 4.03 (ddd, *J* = 13.1, 8.3, 5.8 Hz, 1 H), 3.23 (d, *J* = 6.4 Hz, 2 H), 2.15-1.94 (m, 2 H), 1.39 (s, 9 H), 1.30 (s, 3 H); HRESIMS calcd for C₁₃H₂₁N₄O₅ *m/z* [M + H]⁺ 313.1506, found 313.1499.

Further elution of the above column with 55% EtOAc/petroleum ether and EtOAc gave a product-containing mixture (142 mg). Repeat chromatography of the mixed fractions and fractional crystallization (MeOH/CH₂Cl₂/pentane) gave additional **56** (123 mg, 47%).

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-4-(trifluoromethoxy)benzene-1-sulfonamide (57)**. Deprotection of Boc derivative **56** (58 mg, 0.186 mmol) with 1:1 TFA/CH₂Cl₂ and then reaction of the chromatographed crude amine **38** with 4-(trifluoromethoxy)benzenesulfonyl chloride (0.10 mL, 0.589 mmol) and DIPEA (0.17 mL, 0.976 mmol), using General Procedure E, gave **57** (54 mg, 67%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 200-201 °C; ¹H NMR [(CD₃)₂SO] δ 8.24 (br s, 1 H), 8.05 (s, 1 H), 7.96 (br d, *J* = 8.9 Hz, 2 H), 7.59 (br d, *J* = 8.9 Hz, 2 H), 4.14 (dt, *J* = 13.0, 5.6 Hz, 1 H), 4.05 (ddd, *J* = 13.1, 9.0, 5.4 Hz, 1 H), 3.13 (d, *J* = 14.0 Hz, 1 H), 3.06 (d, *J* = 14.0 Hz, 1 H), 2.20 (ddd, *J* = 14.5, 8.9, 6.0 Hz, 1 H), 2.02 (dt, *J* = 14.4, 5.3 Hz, 1 H), 1.34 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 150.8 (q, *J*_{C-F} = 1.6 Hz), 147.0, 142.2, 139.7, 129.1 (2 C), 121.5 (2 C), 119.9 (q, *J*_{C-F} = 257.4 Hz), 117.7, 80.9, 49.4, 39.3, 27.0, 21.7; HRESIMS calcd for C₁₅H₁₆F₃N₄O₆S *m/z* [M + H]⁺ 437.0737, found 437.0736; HPLC purity: 99.9%.

***N*-[(7-Methyl-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl]-3-(trifluoromethoxy)benzene-1-sulfonamide (58)**. Deprotection of Boc derivative **56** (57.4 mg, 0.184 mmol) with 1:1 TFA/CH₂Cl₂ and then reaction of the chromatographed crude amine **38** with 3-(trifluoromethoxy)benzenesulfonyl chloride (0.10 mL, 0.587 mmol) and DIPEA (0.17 mL, 0.976 mmol), using General Procedure E, gave **58** (65 mg, 81%) as a pale yellow solid: mp (MeOH/CH₂Cl₂/pentane) 162-163 °C; ¹H NMR [(CD₃)₂SO] δ 8.32 (br s, 1 H), 8.06 (s, 1 H), 7.87 (br d, *J* = 7.8 Hz, 1 H), 7.77 (br s, 1 H), 7.75 (t, *J* = 8.0 Hz, 1 H), 7.68 (br d, *J* = 8.2 Hz, 1 H), 4.14 (dt, *J* = 13.0, 5.5 Hz, 1 H), 4.05 (ddd, *J* = 13.1, 9.1, 5.5 Hz, 1 H), 3.14 (d, *J* = 14.0 Hz, 1 H), 3.08 (d, *J* = 14.0 Hz, 1 H), 2.19 (ddd, *J* = 14.4, 9.0, 6.0 Hz, 1 H), 2.02 (dt, *J* = 14.4, 5.3 Hz, 1 H), 1.34 (s, 3 H); HRESIMS calcd for C₁₅H₁₆F₃N₄O₆S *m/z* [M + H]⁺ 437.0737, found 437.0740; HPLC purity: 99.9%.

Synthesis of ether-linked amide 64 (Scheme 3A)

2-Iodo-*N*-[4-(trifluoromethoxy)phenyl]acetamide (62). A mixture of 2-chloro-*N*-[4-(trifluoromethoxy)phenyl]acetamide (**61**) (801 mg, 3.16 mmol) and sodium iodide (5.00 g, 33.4 mmol) in acetone (20 mL) under N₂ was stirred at 56 °C for 2 h and then at 20 °C for 15 h. The resulting mixture was evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with CH₂Cl₂ first gave foreruns and then **62**^{S9} (1.05 g, 96%) as a white solid: mp (CH₂Cl₂/hexane) 140-142 °C (lit.^{S9} mp 140 °C); ¹H NMR (CDCl₃) δ 7.66 (br s, 1 H), 7.54 (br d, *J* = 9.0 Hz, 2 H), 7.21 (br d, *J* = 8.5 Hz, 2 H), 3.86 (s, 2 H); HRESIMS calcd for C₉H₈F₃INO₂ *m/z* [M + H]⁺ 345.9546, found 345.9548.

2-[(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methoxy]-*N*-[4-(trifluoromethoxy)phenyl]acetamide (64). Sodium hydride (60% in mineral oil, 70 mg, 1.75 mmol) was added to a mixture of 7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methanol^{S1} (**63**) (150 mg, 0.704 mmol) and iodide **62** (320 mg, 0.927 mmol) in anhydrous DMF (3 mL) under N₂ at 0 °C. The mixture was immediately degassed and resealed under N₂, and then stirred at 20 °C for 80 min. The resulting mixture was rapidly cooled (CO₂/acetone), quenched with ice/aqueous NaHCO₃ (10 mL), added to brine (40 mL), and extracted with 10% MeOH/CH₂Cl₂ (2 x 50 mL) and CH₂Cl₂ (6 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel. Elution with 0-0.5% MeOH/CH₂Cl₂ first gave foreruns, and then further elution with 0.75% MeOH/CH₂Cl₂ gave the crude product, which was further purified by chromatography on silica gel. Elution with 75% EtOAc/petroleum ether first gave foreruns, and then further elution with EtOAc gave **64** (13 mg, 4%) as a cream solid: mp (CH₂Cl₂/pentane) 122-124 °C; ¹H NMR [(CD₃)₂SO] δ 9.91 (br s, 1 H), 8.08 (s, 1 H), 7.73 (br d, *J* = 9.1 Hz, 2 H), 7.32 (br d, *J* = 8.3 Hz, 2 H), 4.20 (d, *J* = 15.3 Hz, 1 H), 4.19 (dt, *J* = 12.8, 5.9 Hz, 1 H), 4.15 (d, *J* = 15.3 Hz, 1 H), 4.09 (ddd, *J* = 13.0, 8.1, 5.6 Hz, 1 H), 3.74 (d, *J* = 10.7 Hz, 1 H), 3.70 (d, *J* = 10.7 Hz, 1 H), 2.34 (ddd, *J* = 14.5, 8.0, 5.8 Hz, 1 H), 2.09 (dt, *J* = 14.4, 5.8 Hz, 1 H), 1.41 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 168.1, 147.4, 143.7 (q, *J*_{C-F} = 1.5 Hz), 142.2, 137.6, 121.5 (2 C), 121.0 (2 C), 120.1 (q, *J*_{C-F} = 255.6 Hz), 117.7, 81.2, 75.3, 70.5, 39.6, 26.9, 21.5; HRESIMS calcd for C₁₇H₁₈F₃N₄O₆ *m/z* [M + H]⁺ 431.1173, found 431.1174; HPLC purity: 99.5%.

Syntheses of *O*-carbamates **65**, **66**, and **68-74** (Scheme 3B)

(2-Nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)phenyl]carbamate (65). Reaction of alcohol **41**^{S1} (80.3 mg, 0.403 mmol), 1-isocyanato-4-(trifluoromethoxy)benzene (95 μL, 0.630 mmol), and copper(I) chloride (6.5 mg, 0.066 mmol), using General Procedure F, gave **65** (159 mg, 98%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 156-158 °C; ¹H NMR [(CD₃)₂SO] δ 10.07 (br s, 1 H), 8.08 (s, 1 H), 7.57 (br d, *J* = 9.1 Hz, 2 H), 7.31 (br d, *J* = 8.5 Hz, 2 H), 4.87-4.78 (m, 1 H), 4.45 (dd, *J* = 12.3, 2.9 Hz, 1 H), 4.37 (dd, *J* = 12.3, 6.2 Hz, 1 H), 4.17 (ddd, *J* = 12.5, 5.7, 2.5 Hz, 1 H), 4.08 (ddd, *J* = 12.4, 11.4, 5.0 Hz, 1 H), 2.32-2.21 (m, 1 H), 2.18-2.04 (m, 1 H); ¹³C NMR [(CD₃)₂SO] δ 153.1, 147.7, 143.2 (q, *J*_{C-F} = 1.8 Hz), 142.1, 138.2, 121.8 (2 C), 120.1 (q, *J*_{C-F} = 255.5 Hz), 119.5 (2 C), 117.8, 75.9, 64.9, 41.6, 22.3. Anal. (C₁₅H₁₃F₃N₄O₆) C, H, N (see Table S4).

(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)phenyl]carbamate (66). Reaction of alcohol **63**^{S1} (100 mg, 0.469 mmol), 1-isocyanato-4-(trifluoromethoxy)benzene (110 μL, 0.729 mmol), and copper(I) chloride (8.0 mg, 0.081 mmol), using General Procedure F for 32 h, gave **66** (192 mg, 98%) as a cream solid: mp (CH₂Cl₂/pentane) 97-100 °C; ¹H NMR [(CD₃)₂SO] δ 10.03 (br s, 1 H), 8.08 (s, 1 H), 7.56 (br d, *J* = 9.0 Hz, 2 H), 7.30 (br d, *J* = 8.4 Hz, 2 H), 4.32 (s, 2 H), 4.19 (dt, *J* = 13.1, 5.5 Hz, 1 H), 4.12 (ddd, *J* = 13.1, 9.1, 5.5 Hz, 1 H), 2.27 (ddd, *J* = 14.4, 9.0, 6.0 Hz, 1 H), 2.14 (dt, *J* = 14.3, 5.2 Hz, 1 H), 1.44 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 153.0, 147.0, 143.2, 142.2, 138.1, 121.7 (2 C), 120.1 (q, *J*_{C-F} = 255.3 Hz), 119.5 (2 C), 117.8, 80.4, 67.7, 39.3, 26.6, 20.7. Anal. (C₁₆H₁₅F₃N₄O₆) C, H, N (see Table S4).

[(7*R*)-7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl]methyl [4-(trifluoromethoxy)phenyl]carbamate (68). Reaction of [(7*R*)-7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl]methanol^{S2} (**67**) (220 mg, 1.03 mmol), 1-isocyanato-4-

(trifluoromethoxy)benzene (260 μ L, 1.72 mmol), and copper(I) chloride (19 mg, 0.19 mmol), using General Procedure F for 43 h, gave **68** (420 mg, 98%) as a cream solid: mp (CH₂Cl₂/pentane) 140-142 °C; ¹H NMR [(CD₃)₂SO] δ 10.03 (br s, 1 H), 8.09 (s, 1 H), 7.56 (br d, J = 9.0 Hz, 2 H), 7.31 (br d, J = 8.4 Hz, 2 H), 4.32 (s, 2 H), 4.19 (dt, J = 13.1, 5.5 Hz, 1 H), 4.12 (ddd, J = 13.1, 9.2, 5.5 Hz, 1 H), 2.27 (ddd, J = 14.5, 8.9, 6.0 Hz, 1 H), 2.14 (dt, J = 14.4, 5.2 Hz, 1 H), 1.44 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 153.0, 147.0, 143.2 (q, J_{C-F} = 1.4 Hz), 142.2, 138.1, 121.7 (2 C), 120.1 (q, J_{C-F} = 255.4 Hz), 119.5 (2 C), 117.8, 80.4, 67.7, 39.3, 26.6, 20.7; [α]_D²⁵ 32.9 (c 2.007, CHCl₃); Anal. (C₁₆H₁₅F₃N₄O₆) C, H, N (see Table S4).

[(7S)-7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)phenyl]carbamate (69). Reaction of [(7S)-7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methanol^{S2} (*ent*-**67**) (220 mg, 1.03 mmol), 1-isocyanato-4-(trifluoromethoxy)benzene (260 μ L, 1.72 mmol), and copper(I) chloride (15 mg, 0.15 mmol), using General Procedure F for 42 h, gave **69** (421 mg, 98%) as a cream solid: mp (CH₂Cl₂/pentane) 141-143 °C; ¹H NMR [(CD₃)₂SO] δ 10.03 (br s, 1 H), 8.09 (s, 1 H), 7.56 (br d, J = 9.0 Hz, 2 H), 7.31 (br d, J = 8.4 Hz, 2 H), 4.32 (s, 2 H), 4.19 (dt, J = 13.0, 5.5 Hz, 1 H), 4.12 (ddd, J = 13.1, 9.1, 5.5 Hz, 1 H), 2.27 (ddd, J = 14.4, 9.0, 5.9 Hz, 1 H), 2.14 (dt, J = 14.4, 5.2 Hz, 1 H), 1.44 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 153.0, 147.0, 143.2 (q, J_{C-F} = 1.5 Hz), 142.2, 138.1, 121.7 (2 C), 120.1 (q, J_{C-F} = 255.4 Hz), 119.5 (2 C), 117.8, 80.4, 67.7, 39.3, 26.6, 20.7; [α]_D²⁵ -32.4 (c 2.004, CHCl₃). Anal. (C₁₆H₁₅F₃N₄O₆·0.5H₂O) C, H, N (see Table S4). HPLC purity: 99.9%.

(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl [2-(trifluoromethoxy)phenyl]carbamate (70). Reaction of alcohol **63** (100 mg, 0.469 mmol), 1-isocyanato-2-(trifluoromethoxy)benzene (110 μ L, 0.731 mmol), and copper(I) chloride (5.0 mg, 0.051 mmol), using General Procedure F for 52 h, gave **70** (179 mg, 91%) as a cream solid: mp (CH₂Cl₂/pentane) 107-109 °C; ¹H NMR [(CD₃)₂SO] δ 9.56 (br s, 1 H), 8.07 (s, 1 H), 7.68 (br d, J = 8.0 Hz, 1 H), 7.41-7.32 (m, 2 H), 7.25 (td, J = 7.8, 1.7 Hz, 1 H), 4.34 (d, J = 12.0 Hz, 1 H), 4.29 (d, J = 12.0 Hz, 1 H), 4.18 (dt, J = 13.1, 5.7 Hz, 1 H), 4.11 (ddd, J = 13.1, 8.8, 5.5 Hz, 1 H), 2.28 (ddd, J = 14.5, 8.7, 6.1 Hz, 1 H), 2.12 (dt, J = 14.3, 5.4 Hz, 1 H), 1.43 (s, 3 H). Anal. (C₁₆H₁₅F₃N₄O₆) C, H, N (see Table S4).

(2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)benzyl]carbamate (71) and (2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)benzyl]{{[4-(trifluoromethoxy)benzyl]carbamoyl}carbamate (73). Reaction of alcohol **41** (80.1 mg, 0.402 mmol), 1-(isocyanatomethyl)-4-(trifluoromethoxy)benzene^{S8} (160 μ L, ~0.96 mmol), and copper(I) chloride (7.1 mg, 0.072 mmol), using General Procedure F for 40 h, followed by chromatography of the product mixture on silica gel, eluting with 0-3% EtOAc/CH₂Cl₂ (foreruns) and then with 4-6% EtOAc/CH₂Cl₂, first gave crude **73**, which was chromatographed again on silica gel. Elution with 20-50% EtOAc/petroleum ether gave foreruns, and then further elution with EtOAc gave **73** (131 mg, 51%) as a pale yellow solid: mp (pentane triturate) 77-80 °C; ¹H NMR (CDCl₃) δ 8.89 (br t, J = 5.4 Hz, 1 H), 7.40 (s, 1 H), 7.36 (br d, J = 8.7 Hz, 2 H), 7.32 (br d, J = 8.7 Hz, 2 H), 7.20 (br d, J = 7.9 Hz, 2 H), 7.08 (br d, J = 7.9 Hz, 2 H), 5.10 (d, J = 15.5 Hz, 1 H), 4.93 (d, J = 15.5 Hz, 1 H), 4.54 (d, J = 5.7 Hz, 2 H), 4.53-4.43 (m, 3 H), 4.02-3.91 (m, 2 H), 1.99-1.90 (m, 1 H), 1.79-1.64 (m, 1 H); HRESIMS calcd for C₂₅H₂₂F₆N₅O₈ m/z [M + H]⁺ 634.1367, found 634.1374; HPLC purity: 98.2%.

Further elution of the first column above with 10% EtOAc/CH₂Cl₂ gave **71** (74 mg, 44%) as a cream solid: mp (CH₂Cl₂/pentane) 94-97 °C; ¹H NMR [(CD₃)₂SO] δ 8.07 (s, 1 H), 7.97 (br t,

$J = 6.1$ Hz, 1 H), 7.38 (br d, $J = 8.7$ Hz, 2 H), 7.33 (br d, $J = 8.4$ Hz, 2 H), 4.79-4.70 (m, 1 H), 4.33 (dd, $J = 12.3, 3.0$ Hz, 1 H), 4.24 (dd, $J = 12.0, 6.2$ Hz, 1 H), 4.23 (d, $J = 6.2$ Hz, 2 H), 4.15 (ddd, $J = 12.4, 5.6, 2.5$ Hz, 1 H), 4.06 (ddd, $J = 12.3, 11.3, 4.9$ Hz, 1 H), 2.26-2.16 (m, 1 H), 2.13-1.98 (m, 1 H); HRESIMS calcd for $C_{16}H_{16}F_3N_4O_6$ m/z $[M + H]^+$ 417.1016, found 417.1021; HPLC purity: 98.7%.

(7-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)benzyl]carbamate (72) and (7-methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-7-yl)methyl [4-(trifluoromethoxy)benzyl]-{[4-(trifluoromethoxy)benzyl]carbamoyl}carbamate (74). Reaction of alcohol **63** (80.2 mg, 0.376 mmol), 1-(isocyanatomethyl)-4-(trifluoromethoxy)benzene^{S8} (160 μ L, ~0.96 mmol), and copper(I) chloride (8.0 mg, 0.081 mmol), using General Procedure F for 36 h, followed by chromatography of the product mixture on silica gel, eluting with 0-4% EtOAc/ CH_2Cl_2 (foreruns) and then with 4-6% EtOAc/ CH_2Cl_2 , first gave crude **74**, which was chromatographed again on silica gel. Elution with 20-50% EtOAc/petroleum ether gave foreruns, and then further elution with EtOAc gave **74** (112 mg, 46%) as a pale yellow solid: mp (pentane triturate) 77-80 $^{\circ}C$; 1H NMR ($CDCl_3$) δ 8.90 (br t, $J = 5.5$ Hz, 1 H), 7.40 (s, 1 H), 7.37 (br d, $J = 8.7$ Hz, 2 H), 7.30-7.24 (m, 2 H), 7.20 (br d, $J = 8.7$ Hz, 2 H), 7.06 (br d, $J = 7.9$ Hz, 2 H), 5.07 (d, $J = 15.7$ Hz, 1 H), 4.96 (d, $J = 15.7$ Hz, 1 H), 4.54 (d, $J = 5.7$ Hz, 2 H), 4.30 (s, 2 H), 3.94 (ddd, $J = 12.8, 9.9, 5.7$ Hz, 1 H), 3.84 (ddd, $J = 12.8, 5.9$ Hz, 1 H), 1.74 (ddd, $J = 14.3, 5.6, 4.1$ Hz, 1 H), 1.67 (ddd, $J = 14.3, 9.8, 6.1$ Hz, 1 H), 1.29 (s, 3 H); HRESIMS calcd for $C_{26}H_{24}F_6N_5O_8$ m/z $[M + H]^+$ 648.1524, found 648.1538; HPLC purity: 99.9%.

Further elution of the first column above with 8-10% EtOAc/ CH_2Cl_2 gave **72** (80 mg, 49%) as a cream solid: mp (Et₂O/pentane triturate) 76-79 $^{\circ}C$; 1H NMR [$(CD_3)_2SO$] δ 8.07 (s, 1 H), 7.94 (br t, $J = 6.2$ Hz, 1 H), 7.36 (br d, $J = 8.7$ Hz, 2 H), 7.32 (br d, $J = 8.5$ Hz, 2 H), 4.27-4.03 (m, 6 H), 2.22 (ddd, $J = 14.5, 8.5, 5.9$ Hz, 1 H), 2.09 (dt, $J = 14.4, 5.4$ Hz, 1 H), 1.39 (s, 3 H); ^{13}C NMR [$(CD_3)_2SO$] δ 156.0, 147.1 (2 C), 142.2, 139.1, 128.8 (2 C), 120.9 (2 C), 120.1 (q, $J_{C-F} = 255.8$ Hz), 117.7, 80.5, 67.6, 43.1, 39.4, 26.7, 20.9; HRESIMS calcd for $C_{17}H_{18}F_3N_4O_6$ m/z $[M + H]^+$ 431.1173, found 431.1176; HPLC purity: 97.3%.

Minimum Inhibitory Concentration Assays (MABA and LORA). MIC₉₀ data against *Mycobacterium tuberculosis* (*M. tb*, strain H37Rv), representing the lowest concentration values to effect at least 90% growth inhibition, were determined using the standard MABA^{S10} and LORA^{S11} assays, which were conducted at the Institute for Tuberculosis Research (UIC).

In Vitro Parasite Growth Inhibition and Cytotoxicity Assays. All test compounds were screened against the intracellular amastigote stages of *L. inf* and *Trypanosoma cruzi*, and the bloodstream form of *Trypanosoma brucei*, as well as for cytotoxicity toward human MRC-5 cells. These assays were carried out at the University of Antwerp in accordance with the published protocols.^{S12}

Solubility Assessments. The previously reported method was employed.^{S2} Briefly, the solid sample was suspended in water or 0.1 M HCl, sonicated for 15 min, and then centrifuged for 6 min; the clear supernatant was diluted with the same solvent (2-fold) and the solubility was quantified by HPLC (comparing against the peak area recorded from a standard solution).

Microsomal Stability Assays. These metabolism studies were performed by WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China, in line with the recorded procedure,^{S4} in which the compound concentration was 1 μ M and the incubation time was 1 h.

In Vivo Experiments. All animal experiments were conducted according to institutional ethical guidelines for animal care. The LSHTM animal work was performed under a UK Home Office project licence according to the Animal (Scientific Procedures) Act 1986 and the new European Directive 2010/63/EU. The project licence (70/8427) was reviewed by the LSHTM Animal Welfare and Ethical Review Board prior to submission and consequent approval by the UK Home Office.

Acute VL Infection Model (LSHTM). The original protocols were followed.^{S13} Briefly, groups of five female BALB/c mice were infected with 2×10^7 *L. don* amastigotes and, after 7 days, were orally dosed with test compounds (or vehicle alone) once daily for five consecutive days. Parasite load in mouse livers (or spleens) was assessed by microscopic examination of impression smears. Two standard VL drugs, AmBisome and miltefosine (**1**), were also included in each experiment as positive controls.

Mouse Pharmacokinetics. Compounds **65** and **66** were evaluated by WuXi AppTec (Shanghai) Co., Ltd. Each compound was administered to two different groups of three female BALB/c mice (4 groups in total of fasted animals); intravenous dosing (at 1 mg/kg) employed a solution vehicle comprising 20% NMP and 40% PEG-400 in water, whereas oral dosing (at 25 mg/kg) used 7% Tween 80 and 3% EtOH in water. Blood samples collected at various time points post-dose (iv: 0.083, 0.25, 1, 2, 4, 7, 12, and 24 h; oral: 0.25, 1, 2, 4, 6, 8, and 24 h) were transferred into prechilled K2-EDTA tubes and kept on ice until being processed for plasma by centrifugation at 4 °C. Plasma samples were stored at -70 °C prior to analysis by LC-MS/MS, and the PK parameters were determined using Phoenix WinNonlin software (version 6.3).

References for Supporting Information


- (S1) Thompson, A. M.; O'Connor, P. D.; Marshall, A. J.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Braillard, S.; Chatelain, E.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Cooper, C. B.; Denny, W. A. 7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-*b*][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis. *J. Med. Chem.* **2017**, *60*, 4212-4233.
- (S2) Thompson, A. M.; O'Connor, P. D.; Marshall, A. J.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Braillard, S.; Chatelain, E.; Wan, B.; Franzblau, S. G.; Ma, Z.; Cooper, C. B.; Denny, W. A. Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: *In vitro* and *in vivo* appraisal. *Eur. J. Med. Chem.* **2021**, *209*, 112914.
- (S3) Thompson, A. M.; O'Connor, P. D.; Marshall, A. J.; Francisco, A. F.; Kelly, J. M.; Riley, J.; Read, K. D.; Perez, C. J.; Cornwall, S.; Thompson, R. C. A.; Keenan, M.; White, K. L.; Charman, S. A.; Zulfiqar, B.; Sykes, M. L.; Avery, V. M.; Chatelain, E.; Denny, W. A. Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both *in vitro* and *in vivo* trypanocidal efficacy. *Eur. J. Med. Chem.* **2020**, *207*, 112849.
- (S4) Thompson, A. M.; O'Connor, P. D.; Blaser, A.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Martin, D.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-*b*][1,3]oxazoles for neglected tropical diseases: structure-activity studies on a preclinical candidate for visceral leishmaniasis. *J. Med. Chem.* **2016**, *59*, 2530-2550.
- (S5) Thompson, A. M.; O'Connor, P. D.; Marshall, A. J.; Blaser, A.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Braillard, S.; Chatelain, E.; Wan, B.; Franzblau, S. G.; Ma, Z.; Cooper, C. B.; Denny, W. A. Development of (6*R*)-2-nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (DNDI-8219): a new lead for visceral leishmaniasis. *J. Med. Chem.* **2018**, *61*, 2329-2352.
- (S6) Futatsugi, K.; Bahnck, K. B.; Brenner, M. B.; Buxton, J.; Chin, J. E.; Coffey, S. B.; Dubins, J.; Flynn, D.; Gautreau, D.; Guzman-Perez, A.; Hadcock, J. R.; Hepworth, D.; Herr, M.; Hinchey, T.; Janssen, A. M.; Jennings, S. M.; Jiao, W.; Lavergne, S. Y.; Li, B.; Li, M.; Munchhof, M. J.; Orr, S. T. M.; Piotrowski, D. W.; Roush, N. S.; Sammons, M.; Stevens, B. D.; Storer, G.; Wang, J.; Warmus, J. S.; Wei, L.; Wolford, A. C. Optimization of triazole-based TGR5 agonists towards orally available agents. *Med. Chem. Commun.* **2013**, *4*, 205-210.
- (S7) Bezencon, O.; Heidmann, B.; Siegrist, R.; Stamm, S.; Richard, S.; Pozzi, D.; Corminboeuf, O.; Roch, C.; Kessler, M.; Ertel, E. A.; Reymond, I.; Pfeifer, T.; de Kanter, R.; Toeroek-Schafroth, M.; Moccia, L. G.; Mawet, J.; Moon, R.; Rey, M.; Capeleto, B.; Fournier, E. Discovery of a potent, selective T-type calcium channel blocker as a drug candidate for the treatment of generalized epilepsies. *J. Med. Chem.* **2017**, *60*, 9769-9789.
- (S8) Fletcher, S. R.; Hollingworth, G. J.; Jones, A. B.; Moyes, C. R.; Rogers, L. Preparation of heteroaromatic ureas which modulate the function of the vanilloid-1 receptor (VR1). Patent WO 2005028445 A2, 2005.
- (S9) Fest, C.; Reinecke, P.; Brandes, W.; Haenssler, G. Iodoacetamides. Patent DE 3339351 A1, 1985.
- (S10) Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. *In vitro* and *in vivo* activities of macrolide derivatives against *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2005**, *49*, 1447-1454.

- (S11) Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2007**, *51*, 1380-1385.
- (S12) Kaiser, M.; Maes, L.; Tadoori, L. P.; Spangenberg, T.; Ioset, J.-R. Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids. *J. Biomol. Screening* **2015**, *20*, 634-645.
- (S13) Gupta, S.; Yardley, V.; Vishwakarma, P.; Shivahare, R.; Sharma, B.; Launay, D.; Martin, D.; Puri, S. K. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. *J. Antimicrob. Chemother.* **2015**, *70*, 518-527.


Table S4. Combustion analyses for the new compounds of Table 1 and intermediates.

No.	Formula	Calculated			Found		
		C	H	N	C	H	N
15	C ₁₄ H ₁₃ F ₃ N ₄ O ₄	46.93	3.66	15.64	46.89	3.58	15.61
18	C ₁₅ H ₁₅ F ₃ N ₄ O ₄	48.39	4.06	15.05	48.21	4.02	14.98
20	C ₁₄ H ₁₅ ClN ₄ O ₃	52.10	4.68	17.36	52.08	4.69	17.25
22	C ₁₄ H ₁₅ FN ₄ O ₃	54.90	4.94	18.29	54.94	4.92	18.30
24	C ₁₅ H ₁₅ F ₃ N ₄ O ₄	48.39	4.06	15.05	48.38	3.93	15.04
26	C ₁₆ H ₁₇ F ₃ N ₄ O ₄	49.74	4.44	14.50	49.80	4.40	14.57
28	C ₁₅ H ₁₇ ClN ₄ O ₃	53.50	5.09	16.64	53.19	5.10	16.52
30	C ₁₅ H ₁₇ FN ₄ O ₃	56.24	5.35	17.49	56.20	5.27	17.50
32	C ₇ H ₅ F ₃ N ₂ O	44.22	2.65	14.73	44.38	2.54	14.80
37	C ₈ H ₁₀ N ₆ O ₃	40.34	4.23	35.28	40.54	4.26	35.46
42	C ₇ H ₈ N ₆ O ₃	37.50	3.60	37.49	37.80	3.54	37.40
43	C ₁₅ H ₁₃ F ₃ N ₄ O ₅ ·0.5H ₂ O	45.58	3.57	14.17	45.59	3.55	14.04
44	C ₁₆ H ₁₅ F ₃ N ₄ O ₅ ·0.5H ₂ O	46.95	3.94	13.69	47.00	3.95	13.58
45	C ₁₆ H ₁₅ F ₃ N ₄ O ₅	48.01	3.78	14.00	47.97	3.79	13.84
46	C ₁₆ H ₁₅ F ₃ N ₄ O ₅ ·0.25Et ₂ O	48.75	4.21	13.38	48.54	3.84	13.72
49	C ₁₅ H ₁₄ F ₃ N ₅ O ₅	44.90	3.52	17.45	45.06	3.68	17.18
51	C ₁₆ H ₁₆ F ₃ N ₅ O ₅	46.27	3.88	16.86	46.35	3.88	16.63
65	C ₁₅ H ₁₃ F ₃ N ₄ O ₆	44.79	3.26	13.93	45.02	3.20	13.97
66	C ₁₆ H ₁₅ F ₃ N ₄ O ₆	46.16	3.63	13.46	46.44	3.65	13.37
68	C ₁₆ H ₁₅ F ₃ N ₄ O ₆	46.16	3.63	13.46	45.96	3.51	13.20
69	C ₁₆ H ₁₅ F ₃ N ₄ O ₆ ·0.5H ₂ O	45.18	3.79	13.17	45.25	3.63	13.15
70	C ₁₆ H ₁₅ F ₃ N ₄ O ₆	46.16	3.63	13.46	46.20	3.64	13.48

18 (in D₆-DMSO)



18



8.0621
 7.0554
 7.0346
 6.7688
 6.7598
 6.7543
 6.7425
 6.7371
 6.7281
 6.1267
 6.1105
 6.0943
 4.1928
 4.1812
 4.1781
 4.1663
 4.1601
 4.1486
 4.1340
 4.1122
 4.0988
 4.0880
 4.0789
 4.0745
 4.0663
 4.0553
 4.0419
 3.3876
 3.3713
 2.2953
 2.2801
 2.2711
 2.2585
 2.2442
 2.2353
 2.2201
 2.1092
 2.0965
 2.0847
 2.0734
 2.0612
 2.0490
 1.4042


Current Data Parameters
 NAME Aug07-2015-FMHSacsr
 EXPNO 32
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150808
 Time 1.01 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8389.262 Hz
 FIDRES 0.256020 Hz
 AQ 3.9059455 sec
 RG 161.3
 DW 59.600 usec
 DE 10.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 TD0 1
 SFO1 400.1334011 MHz
 NUC1 1H
 P1 11.00 usec

F2 - Processing parameters
 SI 32768
 SF 400.1300024 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

1.0000
 2.0393
 2.0600
 1.0246
 1.0207
 1.0647
 2.0217
 1.0467
 1.0645
 3.0882

18 (in D₆-DMSO)




148.2307
147.3714
142.2077
138.4521
138.4335
124.1296
121.9256
121.6107
119.0865
117.6726
116.5621
112.5070

82.4590

50.6084

27.2128

21.6198





Current Data Parameters
NAME Aug07-2015-FMH5acsrcnmr
EXPNO 33
PROCNO 1

F2 - Acquisition Parameters
Date_ 20150808
Time 6.13 h
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zgpg50
TD 65536
SOLVENT DMSO
NS 9000
DS 4
SWH 26178.010 Hz
FIDRES 0.798889 Hz
AQ 1.2517376 sec
RG 11585.2
DW 19.100 usec
DE 10.00 usec
TE 298.0 K
D1 0.75000000 sec
d11 0.03000000 sec
DELTA 0.64999998 sec
TD0 1
SFO1 100.6248425 MHz
NUC1 13C
P1 11.80 usec
SFO2 400.1316005 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 100.00 usec

F2 - Processing parameters
SI 32768
SF 100.6128173 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

26 (in D₆-DMSO)




```

Current Data Parameters
NAME          Jan11-2016
EXPNO         16
PROCNO        1

F2 - Acquisition Parameters
Date_         20160111
Time          16.16 h
INSTRUM       spect
PROBHD        Z108618_0860 (
PULPROG       zg30
TD            65536
SOLVENT       DMSO
NS            64
DS            2
SWH           8012.820 Hz
FIDRES        0.122266 Hz
AQ            4.0894465 sec
RG            156.54
DW            62.400 usec
DE            6.50 usec
TE            298.0 K
D1            1.00000000 sec
TD0           1
SFO1          400.1324708 MHz
NUC1          1H
P1            13.60 usec
PLW1          13.19999981 W

F2 - Processing parameters
SI            65536
SF            400.1300027 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
    
```

26 (in D₆-DMSO)



26

148.8735
147.1548
142.2254
138.7224
138.7046
124.1277
121.7545
121.5999
119.0753
117.7399
116.5464
112.5438


84.3815

59.1684

40.1995
39.3883

27.3092

21.1922




Current Data Parameters
NAME Jan11-2016
EXPNO 17
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160111
Time 21.31 h
INSTRUM spect
PROBHD Z108618_0860 (
PULPROG zgpg50
TD 65536
SOLVENT DMSO
NS 9000
DS 4
SWH 24038.461 Hz
FIDRES 0.366798 Hz
AQ 1.3631488 sec
RG 198.55
DW 20.800 usec
DE 6.50 usec
TE 298.0 K
D1 0.63999999 sec
D11 0.03000000 sec
TD0 1
SFO1 100.6228298 MHz
NUC1 13C
P1 10.00 usec
PLW1 48.17399979 W
SFO2 400.1316005 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 13.19999981 W
PLW12 0.30142000 W
PLW13 0.15161000 W

F2 - Processing parameters
SI 32768
SF 100.6128171 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

40 (in CDCl₃)





Current Data Parameters
 NAME Aug15-2019
 EXPNO 16
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190815
 Time 16.39 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 176.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300082 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

40 (in CDCl₃)




Current Data Parameters
 NAME Aug15-2019
 EXPNO 17
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190816
 Time 4.09 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zgpg50
 TD 65536
 SOLVENT CDCl3
 NS 20000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6127480 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

44 (in D₆-DMSO)




8.8601
8.8452
8.8301

8.0752
8.0165
7.9949

7.4801
7.4594

4.2354
4.2221
4.2039
4.1895
4.1763
4.1038
4.0898
4.0833
4.0697
4.0576
4.0506
4.0362
3.6635
3.6474
3.6282
3.6146
3.6016
3.5818
3.5664
2.2151
2.1945
2.1791
2.1585
2.1436
2.1127
2.1000
2.0865
2.0639
2.0509
1.3949



Current Data Parameters
NAME Aug07-2015-FMHSacsr
EXPNO 50
PROCNO 1

F2 - Acquisition Parameters
Date_ 20150810
Time 1.20 h
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 64
DS 2
SWH 8389.262 Hz
FIDRES 0.256020 Hz
AQ 3.9059455 sec
RG 161.3
DW 59.600 usec
DE 10.00 usec
TE 298.0 K
D1 2.00000000 sec
TD0 1
SFO1 400.1334011 MHz
NUC1 1H
P1 11.00 usec

F2 - Processing parameters
SI 32768
SF 400.1300021 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

1.0000

3.0472

2.0719

1.0070

1.0216

2.0419



0.9885

1.0458

3.1253

44 (in D₆-DMSO)

165.8952
 150.3295
 147.2736
 142.2368
 133.2634
 129.8184
 123.7785
 121.2257
 120.5837
 118.6699
 117.6867
 116.1221
 81.8020
 46.0177
 27.4141
 22.0957



Current Data Parameters
 NAME Aug07-2015-FMHSacsrcnmr
 EXPNO 51
 PROCNO 1



F2 - Acquisition Parameters

Date_ 20150810
 Time 6.32 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 9000
 DS 4
 SWH 26178.010 Hz
 FIDRES 0.798889 Hz
 AQ 1.2517376 sec
 RG 11585.2
 DW 19.100 usec
 DE 10.00 usec
 TE 298.0 K
 D1 0.75000000 sec
 d11 0.03000000 sec
 DELTA 0.64999998 sec
 TD0 1
 SFO1 100.6248425 MHz
 NUC1 13C
 P1 11.80 usec
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 100.00 usec

F2 - Processing parameters

SI 32768
 SF 100.6128170 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

45 (in D₆-DMSO)





Current Data Parameters
 NAME Dec04-2020
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20201205
 Time 14.55 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 176.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

45 (in D₆-DMSO)





Current Data Parameters
 NAME Dec04-2020
 EXPNO 6
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20201205
 Time 21.49 h
 INSTRUM spect
 PROBHD z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128174 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

47 (in D₆-DMSO)





Current Data Parameters
 NAME May29-2020
 EXPNO 37
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200601
 Time 17.40 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 156.54
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

47 (in D₆-DMSO)





Current Data Parameters
 NAME May29-2020
 EXPNO 38
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200602
 Time 0.35 h
 INSTRUM spect
 PROBHD Z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 297.8 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SF01 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128172 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

49 (in D₆-DMSO)




Current Data Parameters
 NAME Jan25-2017
 EXPNO 20
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20170126
 Time 0.38 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 176.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300025 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

49 (in D₆-DMSO)



155.0826
 147.8975
 142.1447
 142.1290
 142.0218
 139.5676
 123.9838
 121.6278
 121.4442
 118.9116
 118.7448
 117.7618
 116.3655
 77.3064
 42.1403
 41.7051
 23.4004





Current Data Parameters
 NAME Jan25-2017
 EXPNO 21
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20170126
 Time 8.42 h
 INSTRUM spect
 PROBHD Z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 14000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128174 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

51 (in D₆-DMSO)




Current Data Parameters
 NAME Aug07-2015-FMHSacsr
 EXPNO 48
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150809
 Time 19.58 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8389.262 Hz
 FIDRES 0.256020 Hz
 AQ 3.9059455 sec
 RG 161.3
 DW 59.600 usec
 DE 10.00 usec
 TE 298.0 K
 D1 2.00000000 sec
 TD0 1
 SFO1 400.1334011 MHz
 NUC1 1H
 P1 11.00 usec

F2 - Processing parameters
 SI 32768
 SF 400.1300024 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

51 (in D₆-DMSO)




155.2004
 147.2359
 142.2239
 142.1545
 142.1388
 139.5484
 131.5225
 128.8054
 123.9870
 121.6529
 121.4528
 118.9157
 118.6997
 117.7389
 116.3803

81.9515

46.0853

27.1541

21.4678



Current Data Parameters
 NAME Aug07-2015-FMHSacsrcnmr
 EXPNO 4
 PROCNO 1


F2 - Acquisition Parameters

Date_ 20150810
 Time 1.10 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 9000
 DS 4
 SWH 26178.010 Hz
 FIDRES 0.798889 Hz
 AQ 1.2517376 sec
 RG 11585.2
 DW 19.100 usec
 DE 10.00 usec
 TE 298.0 K
 D1 0.75000000 sec
 d11 0.03000000 sec
 DELTA 0.64999998 sec
 TD0 1
 SFO1 100.6248425 MHz
 NUC1 13C
 P1 11.80 usec
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 100.00 usec

F2 - Processing parameters

SI 32768
 SF 100.6128164 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

55 (in D₆-DMSO)





Current Data Parameters
 NAME Jun12-2020
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200612
 Time 23.20 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 198.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

55 (in D₆-DMSO)





Current Data Parameters
NAME Jun12-2020
EXPNO 12
PROCNO 1

F2 - Acquisition Parameters
Date_ 20200613
Time 9.41 h
INSTRUM spect
PROBHD Z108618_0860 ()
PULPROG zgpg50
TD 65536
SOLVENT DMSO
NS 18000
DS 4
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 1.3631488 sec
RG 198.55
DW 20.800 usec
DE 6.50 usec
TE 298.0 K
D1 0.63999999 sec
D11 0.03000000 sec
TD0 1
SF01 100.6228298 MHz
NUC1 13C
P1 10.00 usec
PLW1 48.17399979 W
SFO2 400.1316005 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 13.19999981 W
PLW12 0.30142000 W
PLW13 0.15161000 W

F2 - Processing parameters
SI 32768
SF 100.6128174 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

57 (in D₆-DMSO)




```

Current Data Parameters
NAME          Aug14-2019
EXPNO         15
PROCNO        1


F2 - Acquisition Parameters
Date_         20190814
Time          17.19 h
INSTRUM       spect
PROBHD        Z108618_0860 (
PULPROG       zg30
TD            65536
SOLVENT       DMSO
NS            64
DS            2
SWH           8012.820 Hz
FIDRES        0.244532 Hz
AQ            4.0894465 sec
RG            176.55
DW            62.400 usec
DE            6.50 usec
TE            298.0 K
D1            1.00000000 sec
TD0           1
SFO1          400.1324708 MHz
NUC1          1H
P0            4.53 usec
P1            13.60 usec
PLW1          13.19999981 W

F2 - Processing parameters
SI            65536
SF            400.1300026 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
    
```

57 (in D₆-DMSO)



150.7613
150.7456
146.9778
142.1753
139.7497
129.0521
123.6948
121.4687
121.1336
118.5687
117.6904
116.0192




Current Data Parameters
 NAME Aug14-2019
 EXPNO 16
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190815
 Time 4.49 h
 INSTRUM spect
 PROBHD Z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 20000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128176 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

64 (in D₆-DMSO)




Current Data Parameters
 NAME Jun19-2020
 EXPNO 13
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200621
 Time 6.22 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 198.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

64 (in D₆-DMSO)




Current Data Parameters
 NAME Jun19-2020
 EXPNO 14
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200622
 Time 5.20 h
 INSTRUM spect
 PROBHD Z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 40000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128177 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

65 (in D₆-DMSO)




Current Data Parameters
 NAME Jan12-2016
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160112
 Time 16.11 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.122266 Hz
 AQ 4.0894465 sec
 RG 176.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P1 13.60 usec
 PLW1 13.19999981 W


F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

65 (in D₆-DMSO)



153.0901
 147.6661
 143.1798
 143.1617
 142.0575
 138.1884
 123.9444
 121.7574
 121.4040
 119.4817
 118.8654
 117.7831
 116.3270

75.9260
 64.9095
 41.6465
 22.2635





Current Data Parameters
 NAME Jan12-2016
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160112
 Time 23.06 h
 INSTRUM spect
 PROBHD Z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.366798 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128164 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

66 (in D₆-DMSO)




Current Data Parameters
 NAME Aug07-2015-FMHSacsr
 EXPNO 46
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150809
 Time 14.36 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8389.262 Hz
 FIDRES 0.256020 Hz
 AQ 3.9059455 sec
 RG 228.1
 DW 59.600 usec
 DE 10.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 TD0 1
 SFO1 400.1334011 MHz
 NUC1 1H
 P1 11.00 usec

F2 - Processing parameters
 SI 32768
 SF 400.130024 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

66 (in D₆-DMSO)




153.0118
 147.0331
 143.1685
 142.2205
 138.1476
 123.9348
 121.7443
 121.3958
 119.5012
 118.8586
 117.7712
 116.3188

80.3969

67.7149

26.5717

20.6967





Current Data Parameters
 NAME Aug07-2015-FMHsacsrcnmr
 EXPNO 47
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150809
 Time 19.48 h
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 9000
 DS 4
 SWH 26178.010 Hz
 FIDRES 0.798889 Hz
 AQ 1.2517376 sec
 RG 11585.2
 DW 19.100 usec
 DE 10.00 usec
 TE 298.0 K
 D1 0.75000000 sec
 d11 0.03000000 sec
 DELTA 0.64999998 sec
 TD0 1
 SFO1 100.6248425 MHz
 NUC1 13C
 P1 11.80 usec
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 100.00 usec

F2 - Processing parameters
 SI 32768
 SF 100.6128169 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

68 (in D₆-DMSO)




Current Data Parameters
 NAME Dec04-2020
 EXPNO 11
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20201206
 Time 9.35 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 176.55
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

68 (in D₆-DMSO)



153.0099
 147.0318
 143.1809
 143.1666
 142.2170
 138.1483
 123.9334
 121.7486
 121.3947
 119.4988
 118.8569
 117.7762
 116.3183
 80.3958
 67.7138
 26.5672
 20.6946




Current Data Parameters
 NAME Dec04-2020
 EXPNO 12
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20201206
 Time 16.30 h
 INSTRUM spect
 PROBHD z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128171 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

69 (in D₆-DMSO)



10.0309
8.0852
7.5749
7.5523
7.3157
7.3141
7.2932
4.3238
4.2237
4.2099
4.1955
4.1908
4.1777
4.1635
4.1527
4.1390
4.1299
4.1163
4.1063
4.0970
4.0834
2.3313
2.3266
2.3219
2.3102
2.2951
2.2875
2.2734
2.2590
2.2516
2.2364
2.1675
2.1544
2.1414
2.1316
2.1186
2.1056
1.4416





10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm

1.0000
0.9758
1.9803
2.0080
2.0245
2.0276
1.0387
1.0091
3.0123

Current Data Parameters
 NAME Dec04-2020
 EXPNO 14
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20201206
 Time 18.56 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 156.54
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W
 F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

69 (in D₆-DMSO)





Current Data Parameters
 NAME Dec04-2020
 EXPNO 15
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20201207
 Time 1.50 h
 INSTRUM spect
 PROBHD z108618_0860 ()
 PULPROG zgpg50
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 198.55
 DW 20.800 usec
 DE 6.50 usec
 TE 298.0 K
 D1 0.63999999 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 P1 10.00 usec
 PLW1 48.17399979 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 13.19999981 W
 PLW12 0.30142000 W
 PLW13 0.15161000 W

F2 - Processing parameters
 SI 32768
 SF 100.6128173 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

72 (in D₆-DMSO)




Current Data Parameters
 NAME Dec04-2020
 EXPNO 8
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20201206
 Time 0.15 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 156.54
 DW 62.400 usec
 DE 6.50 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300026 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

72 (in D₆-DMSO at 313K)





Current Data Parameters
 NAME Sep05-2019
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190905
 Time 10.59 h
 INSTRUM spect
 PROBHD Z108618_0860 (
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0894465 sec
 RG 198.55
 DW 62.400 usec
 DE 6.50 usec
 TE 313.3 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.1324708 MHz
 NUC1 1H
 P0 4.53 usec
 P1 13.60 usec
 PLW1 13.19999981 W

F2 - Processing parameters
 SI 65536
 SF 400.1300027 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

72 (in D₆-DMSO at 328K)




```

Current Data Parameters
NAME      Sep05-2019
EXPNO    3
PROCNO   1


F2 - Acquisition Parameters
Date_    20190905
Time     11.13 h
INSTRUM  spect
PROBHD   Z108618_0860 (
PULPROG  zg30
TD        65536
SOLVENT  DMSO
NS        64
DS        2
SWH       8012.820 Hz
FIDRES    0.244532 Hz
AQ        4.0894465 sec
RG        198.55
DW        62.400 usec
DE        6.50 usec
TE        328.0 K
D1        1.00000000 sec
TD0       1
SFO1     400.1324708 MHz
NUC1      1H
P0        4.53 usec
P1        13.60 usec
PLW1     13.19999981 W

F2 - Processing parameters
SI        65536
SF        400.1300028 MHz
WDW       EM
SSB       0
LB        0.30 Hz
GB        0
PC        1.00
    
```


72 (in D₆-DMSO - variable temperature spectra overlaid)



72 (in D₆-DMSO)



156.0074
 147.1472
 142.1822
 139.0779
 128.7600
 123.8864
 121.3461
 120.9498
 120.7702
 118.8030
 117.7469
 116.2598
 80.4649
 67.6036
 43.0778
 26.7376
 20.8919



```

Current Data Parameters
NAME          Dec04-2020
EXPNO         9
PROCNO        1

F2 - Acquisition Parameters
Date_         20201206
Time          7.09 h
INSTRUM       spect
PROBHD        z108618_0860 (
PULPROG       zgpg50
TD            65536
SOLVENT       DMSO
NS            12000
DS            4
SWH           24038.461 Hz
FIDRES        0.733596 Hz
AQ            1.3631488 sec
RG            198.55
DW            20.800 usec
DE            6.50 usec
TE            298.0 K
D1            0.63999999 sec
D11           0.03000000 sec
TD0           1
SFO1          100.6228298 MHz
NUC1          13C
P1            10.00 usec
PLW1          48.17399979 W
SFO2          400.1316005 MHz
NUC2          1H
CPDPRG[2]    waltz16
PCPD2         90.00 usec
PLW2          13.19999981 W
PLW12         0.30142000 W
PLW13         0.15161000 W

F2 - Processing parameters
SI            32768
SF            100.6128171 MHz
WDW           EM
SSB           0
LB            1.00 Hz
GB            0
PC            1.40
    
```